<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">49020</article-id><article-id pub-id-type="doi">10.7554/eLife.49020</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-144540"><name><surname>Wang</surname><given-names>Shixiang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9855-7357</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144541"><name><surname>He</surname><given-names>Zaoke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144542"><name><surname>Wang</surname><given-names>Xuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144543"><name><surname>Li</surname><given-names>Huimin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-124268"><name><surname>Liu</surname><given-names>Xue-Song</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7736-0077</contrib-id><email>liuxs@shanghaitech.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">School of Life Science and Technology</institution><institution>ShanghaiTech University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Freeman</surname><given-names>Gordon</given-names></name><role>Reviewing Editor</role><aff><institution>Dana-Farber Cancer Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>26</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e49020</elocation-id><history><date date-type="received" iso-8601-date="2019-06-04"><day>04</day><month>06</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-10-21"><day>21</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Wang et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-49020-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.49020.001</object-id><p>Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients who are more likely to respond to immunotherapy. The fundamental basis for ICI response is the immunogenicity of a tumor, which is primarily determined by tumor antigenicity and antigen presentation efficiency. Here, we propose a method to measure tumor immunogenicity score (TIGS), which combines tumor mutational burden (TMB) and an expression signature of the antigen processing and presenting machinery (APM). In both correlation with pan-cancer ICI objective response rates (ORR) and ICI clinical response prediction for individual patients, TIGS consistently showed improved performance compared to TMB and other known prediction biomarkers for ICI response. This study suggests that TIGS is an effective tumor-inherent biomarker for ICI-response prediction.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.49020.002</object-id><title>eLife digest</title><p>In the last decade a new kind of cancer therapy, called immunotherapy, has changed how doctors treat cancer patients. These therapies mean that previously incurable cancers, including some skin and lung cancers, can now sometimes be cured. Immunotherapy does this by activating the patient’s own immune system so that it will attack the cancer cells. But for this to work, the cancer cells, much like invading bacteria or viruses, need to be recognized as foreign.</p><p>Cancer cells contain many DNA mutations that cause the cell to make mutated proteins it would not normally make. These proteins betray the cancer cells as foreign to the immune system. The extent to which cancer cells make mutated proteins – also called the ‘tumor mutational burden’ – can sometimes predict whether a patient will respond to immunotherapy. In general, patients with a high mutational burden respond well to immunotherapy, but overall fewer than one in five cancer patients are cured by this treatment.</p><p>An important question is whether there are better ways of predicting if a cancer patient will respond to immunotherapy. Wang et al. have addressed this problem by adding a second variable to the prediction. Not only do cancer cells have to make mutated proteins, but these proteins also have to be ‘seen’ by immune cells. Cancer cells, like normal cells, have mechanisms to present protein fragments to immune cells. Wang et al. hypothesized that patients with a high mutational burden would not respond to immunotherapy if they were lacking the machinery required for presenting protein fragments.</p><p>The experiments revealed that measuring both tumor mutational burden and the levels of the machinery that presents protein fragments resulted in better predictions of patients’ responses to immunotherapy than measuring tumor mutational burden alone. Additionally, this new way of predicting responses to immunotherapy was successful across many different cancer types.</p><p>The combined measurement of these two variables could be applied in clinical practice as a way to predict cancer patients’ response to immunotherapy. This should allow doctors to determine which course of treatment will work best for a specific patient. The results also suggest that inducing tumor cells to produce more of the machinery that presents protein fragments to the immune system could increase their responsiveness to immunotherapy. In the future, predicting how well a patient will respond to immunotherapy could become even more accurate by incorporating additional variables.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>tumor immunogenicity</kwd><kwd>antigen presentation</kwd><kwd>tumor mutational burden</kwd><kwd>cancer immunotherapy</kwd><kwd>immune checkpoint inhibitors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31771373</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Xue-Song</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Immunotherapy, represented by immune checkpoint inhibitors (ICI), including anti-PD-1 antibodies, anti-PD-L1 antibodies, anti CTLA-4 antibodies or their combinations, is transforming the treatment of cancer. Compared to conventional therapies, ICI can induce significantly improved clinical responses in patients with various types of late-stage metastatic cancers. However, the majority of unselected patients will not respond to ICI. Most tumor types show response rates below 40% to PD-1 inhibition, and the response rates of each tumor type are reported to be correlated with the tumor mutational burden (TMB) of that tumor type (<xref ref-type="bibr" rid="bib48">Yarchoan et al., 2017</xref>). Multiple factors are reported to affect ICI effectiveness, including: PD-L1 expression (<xref ref-type="bibr" rid="bib14">Herbst et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Shukuya and Carbone, 2016</xref>), TMB (<xref ref-type="bibr" rid="bib31">Rizvi et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Snyder et al., 2014</xref>), DNA mismatch repair deficiency (<xref ref-type="bibr" rid="bib18">Le et al., 2015</xref>), the degree of cytotoxic T cell infiltration (<xref ref-type="bibr" rid="bib40">Tang et al., 2016</xref>), mutational signature (<xref ref-type="bibr" rid="bib26">Miao et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Wang et al., 2018</xref>), antigen presentation defects (<xref ref-type="bibr" rid="bib7">Chowell et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Zaretsky et al., 2016</xref>), interferon signaling (<xref ref-type="bibr" rid="bib1">Ayers et al., 2017</xref>), tumor aneuploidy (<xref ref-type="bibr" rid="bib10">Davoli et al., 2017</xref>) and T-cell signatures (<xref ref-type="bibr" rid="bib17">Jiang et al., 2018</xref>). These biomarkers have various rates of accuracy and utility, and the identification of a robust ICI-response biomarker is still a critical challenge in the field (<xref ref-type="bibr" rid="bib28">Nishino et al., 2017</xref>).</p><p>ICI help a patient’s immune system to recognize and attack cancer cells. The immunogenicity of cancer cells is the fundamental determinant of ICI response. Theoretically, tumors of very low or no immunogenicity will not respond to therapeutic strategies that enhance the immune response. Hence, ICI can only be used to treat tumors that have sufficient immunogenicity. Furthermore, enhancing tumor immunogenicity can potentially transform an immunotherapy-non-responsive tumor into an immunotherapy-responsive tumor.</p><p>The actual immunogenicity of a tumor is not easy to measure. In theory, tumor immunogenicity is determined by the tumor cell itself, and is also influenced by factors related to the tumor microenvironment, such as the functioning of professional antigen-presenting cells like dendritic cells (DCs) (<xref ref-type="bibr" rid="bib25">Mellman and Steinman, 2001</xref>). Fundamental determinants of tumor immunogenicity include tumor antigenicity, and antigen processing and presenting efficiency (<xref ref-type="bibr" rid="bib4">Blankenstein et al., 2012</xref>).</p><p>Antigen presentation defects have already been shown to contribute to ICI-response failure (<xref ref-type="bibr" rid="bib7">Chowell et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Zaretsky et al., 2016</xref>). To measure antigen processing and presenting efficiency systematically, we applied a gene set variation analysis (GSVA) method to generate an antigen processing and presenting machinery (APM) score (APS) (<xref ref-type="bibr" rid="bib12">Hänzelmann et al., 2013</xref>), which was calculated from the mRNA expression status of APM genes. Tumor immunogenicity score (TIGS) was then calculated by combining the APM score and the TMB. The antigen-presentation gene expression signature and tumor immunogenicity landscape of 32 cancer types from The Cancer Genome Atlas (TCGA) project are provided.</p><p>TIGS exhibits improved performance in both pan-cancer ICI objective response rate (ORR) correlation and accuracy of ICI clinical response prediction when compared with TMB. Our results suggest that TIGS represents a novel and effective tumor-inherent biomarker for the prediction of immunotherapy response.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>APM score definition and pan-cancer analysis</title><p>Cell surface presentation of peptides by major histocompatibility complex (MHC) class I molecules is critical to CD8<sup>+</sup> T-cell mediated adaptive immune responses, including those against tumors. The generation and loading of peptides onto MHC class I molecules require the functioning of the APM. Several steps are involved in this process, including: 1) peptide generation and trimming in the proteasome; 2) peptide transport; 3) assembly of the MHC class loading complex in the endoplasmic reticulum (ER); and 4) antigen presentation on cell surface (<xref ref-type="bibr" rid="bib19">Leone et al., 2013</xref>).</p><p>The efficiency of antigen processing and presentation is one determinant of tumor immunogenicity. Here, we used the mRNA expression status of genes involved in the APM process as an indicator of the efficiency of these antigen-processing and -presenting steps. A GSVA approach was applied to measure the overall expression enrichment of APM genes (<xref ref-type="bibr" rid="bib12">Hänzelmann et al., 2013</xref>). On the basis of a review paper about APM (<xref ref-type="bibr" rid="bib19">Leone et al., 2013</xref>), the following genes were selected for quantification: <italic>PSMB5</italic>, <italic>PSMB6</italic>, <italic>PSMB7</italic>, <italic>PSMB8</italic>, <italic>PSMB9</italic>, <italic>PSMB10</italic>, <italic>TAP1</italic>, <italic>TAP2</italic>, <italic>ERAP1</italic>, <italic>ERAP2</italic>, <italic>CANX</italic>, <italic>CALR</italic>, <italic>PDIA3</italic>, <italic>TAPBP</italic>, <italic>B2M</italic>, <italic>HLA-A</italic>, <italic>HLA-B</italic> and <italic>HLA-C</italic> (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). GSVA calculates the per sample overexpression level of a particular gene list by comparing the ranks of the genes in that list with those of all other genes. The resulting GSVA enrichment score is defined as the APS.</p><p>To explore the pan-cancer distribution pattern of APS, we analyzed about 10,000 tumors of 32 cancer types from TCGA (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The boxplot in <xref ref-type="fig" rid="fig1">Figure 1A</xref> shows large variance in APS across TCGA cancer types, which uncovers significant distinction in antigen-processing and -presenting efficiency among different cancer types. This analysis is similar to a previous study of seven APM genes (<xref ref-type="bibr" rid="bib35">Şenbabaoğlu et al., 2016</xref>) whose expression signature is highly correlated with the APS quantified in this study (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Patient Harmonic Best Rank (PHBR) I and II scores have recently been proposed to quantify a patient’s antigen presentation ability on the basis of the genotypes of their MHC class I or class II genes, respectively (<xref ref-type="bibr" rid="bib23">Marty Pyke et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Marty et al., 2017</xref>). However, no significant correlations can be observed between APS and PHBR scores (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), probably because these two methods capture different information about antigen presentation: PHBR are based on MHC genotype information, whereas APS are based on information about the expression of antigen-presentation genes. Univariate Cox regression analyses suggest that APS is associated with cancer patients' survival, and some are statistically significant (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Meta-analysis with pan-cancer hazard ratio values suggests that APS do not associate with prognosis (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.49020.003</object-id><label>Figure 1.</label><caption><title>Analysis of antigen processing and presenting machinery (APM) score in 32 cancer types.</title><p>(<bold>A</bold>) APM scores were calculated with GSVA in 32 TCGA cancer types. (<bold>B</bold>) Results of Cox proportional hazards regression analysis using APM score for all solid cancers. Forest plots showing log<sub>e</sub> hazard ratio (95% confidence interval). Cox p-values are adjusted the with false discovery rate (FDR) method, p-values less than 0.1 are in bold. The pooled hazard ratio and p-value are generated by the random effect model. The statistical test for heterogeneity is also shown in the last column. Tumor types are ordered by median APM scores.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.49020.005</object-id><label>Figure 1—source data 1.</label><caption><title>APM gene list for GSVA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49020-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Correlations between immune infiltration score (IIS), APS, 7-APM genes, PHBR I and PHBR II in the TCGA pan-cancer dataset.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>APS determinants and associations in cancer</title><p>To identify the specific gene signatures that determine patients’ APS status, we initially ran differential gene expression analysis for each TCGA cancer type on the basis of APS status. Patients with APS above the median were defined as ‘APS-High’, patients with APS below the median were defined as ‘APS-Low’. Differential expression genes (p-value &lt; 0.01, FDR &lt; 0.05) were ranked by logFC from high to low and then selected for gene set enrichment analysis (GSEA) with gene sets from MSigDB (<xref ref-type="bibr" rid="bib39">Subramanian et al., 2005</xref>). In results from hallmark gene sets, several gene signatures (especially interferon alpha/gamma response) were found to be enriched in most TCGA cancer types with high APS, suggesting that high APS is strongly associated with the interferon alpha/gamma signaling pathway (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). GSEA using Reactome gene sets further validated this result (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Interestingly, interferon gamma was reported to regulate APM gene expression (<xref ref-type="bibr" rid="bib2">Beatty and Paterson, 2001</xref>; <xref ref-type="bibr" rid="bib16">Ikeda et al., 2002</xref>), which is consistent with this observation.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.49020.006</object-id><label>Figure 2.</label><caption><title>Gene expression signatures associated with high APM score.</title><p>(<bold>A</bold>) Gene sets enriched in patients with high APM score. (<bold>B</bold>) Significant correlation between APM score and IIS in 8949 cancer samples. (<bold>C</bold>) Significant correlation between APM score and IIS in different cancer types. (<bold>D</bold>) Correlation between TMB and IIS in 8413 cancer samples. (<bold>E</bold>) Correlation between TMB and IIS in different cancer types.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.49020.011</object-id><label>Figure 2—source data 1.</label><caption><title>Immune cell types and corresponding signature gene lists for GSVA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49020-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Gene sets that are enriched in 30 types of TCGA cancer patients with high APM score.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Correlation between IIS of GSVA and TIMER analysis (B_cell, etc.) results in 30 TCGA cancer types.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.009</object-id><label>Figure 2—figure supplement 3.</label><caption><title>Analysis of tumor mutational burden (TMB) in 32 TCGA cancer types.</title><p>(<bold>A</bold>) Number of whole-exome non-synonymous mutation in 32 TCGA cancer types. (<bold>B</bold>) Results of Cox proportional hazards regression analysis using TMB for all solid cancers. Forest plots showing log<sub>e</sub> hazard ratio (95% confidence interval). Cox p-values are adjusted with the FDR method. p-values less than 0.1 are in bold. The pooled hazard ratio and p-value are generated by the random effect model. The statistical test for heterogeneity is also shown in the last column. Tumor types are ordered by median TMB values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.010</object-id><label>Figure 2—figure supplement 4.</label><caption><title>Immune cell subsets associated with APS were analyzed with IIS (<bold>A</bold>) or the CIBERSORT (<bold>B</bold>) method.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig2-figsupp4-v1.tif"/></fig></fig-group><p>Immune infiltration score (IIS) was calculated with GSVA using a list of marker genes for immune cell types and has been validated by the CIBERSORT method (<xref ref-type="bibr" rid="bib35">Şenbabaoğlu et al., 2016</xref>) (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). TIMER (<xref ref-type="bibr" rid="bib20">Li et al., 2016</xref>) is another method that can accurately resolve the relative fractions of diverse cell types on the basis of gene expression profiles from complex tissues. To further validate the calculated IIS, we performed TIMER analysis (<xref ref-type="bibr" rid="bib20">Li et al., 2016</xref>) and found that the TIMER results were highly correlated with the calculated IIS (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Significant associations between APS and IIS at both the level of cancer types and the level of individual patients were observed (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). The gene list for APS calculation did not overlap with the gene list for IIS calculation.</p><p>Pan-cancer distribution of TMB was also analyzed with the TCGA dataset (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Different cancer types show different prognosis in relation to high TMB (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Meta-analysis including all TCGA cancer types suggests that patients with high TMB tend to have poor prognosis (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). TMB reflects tumor antigenicity and predicted improved survival after immunotherapy. However, in cancer patients not treated with immunotherapy, high TMB tends to be associated with poor prognosis, probably because tumors accumulate mutations during progression as a result of genome instability, and consequently, high TMB is usually associated with late-stage cancer.</p><p>The immune cell subsets were assessed with both IIS and CIBERSORT (<xref ref-type="bibr" rid="bib27">Newman et al., 2015</xref>) methods, and the associations between immune cell subsets with APS were analyzed further (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). Several types of immune cells, including cytotoxic cells, show strong correlation with APS values (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). TMB and IIS show relatively weak intercorrelation (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). The significant correlation between APS and IIS could be due to the following reasons: first, the immune response coordinated by interferon signaling could regulate both APS and IIS; and second, the immunogenicity contributed by APS could stimulate immune response.</p></sec><sec id="s2-3"><title>Tumor immunogenicity score: definition and pan-cancer profiling</title><p>Tumor immunogenicity is determined by two factors: the antigenicity of tumor cells and the processing and presentation of tumor antigens. These two factors are independent, and are both required for tumor immunogenicity determination. Theoretically, tumor immunogenicity score (TIGS) can be represented as [“Tumor antigenicity”] x [“Antigen processing and presenting status”].</p><p>Non-synonymous tumor mutation and, consequently, the production of neoantigens can elicit immune response (<xref ref-type="bibr" rid="bib34">Schumacher and Schreiber, 2015</xref>). Pan-cancer TMB distribution was analyzed, and log-based TMB values were found to show a Gaussian distribution (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In addition, a previous study had already indicated that log(TMB) shows linear correlation with pan-cancer immunotherapy ORR (<xref ref-type="bibr" rid="bib48">Yarchoan et al., 2017</xref>). Thus, we used log(TMB) as a simple representation of ‘Tumor antigenicity’. APS calculated on the basis of GSVA range from −1 to 1. To multiply with tumor antigenicity, we used normalized APS values, which range from 0 to 1, as a representation of ‘Antigen processing and presenting status’.<disp-formula id="equ1"><mml:math id="m1"><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo> <mml:mi/><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo>_</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo>_</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo> <mml:mi/><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo>_</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>We calculated tumor immunogenicity score (TIGS) by using the following formula:<disp-formula id="equ2"><label>(TMB)</label><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo> <mml:mi/><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub> <mml:mi/><mml:mo>×</mml:mo> <mml:mi/><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo>⁡</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>M</mml:mi><mml:mi>B</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>TIGS were calculated for TCGA samples for which both TMB and RNA-seq gene expression data are available (32 cancer types, 8413 samples) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Cancer types with high TIGS include: skin cutaneous melanoma (SKCM), diffuse large B-cell lymphoma (DLBC), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Univariate Cox regression analysis suggests that TIGS is associated with cancer patients' survival, and this association is statistically significant for some cancer types (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Meta-analysis involving all TCGA cancer types suggested that high TIGS tends to be associated with a poor prognosis in patients not treated with immunotherapy (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), which may be due to a mechanism that is the same as that which leads to high TMB.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.49020.012</object-id><label>Figure 3.</label><caption><title>Tumor immunogenicity score (TIGS) analysis in 32 cancer types.</title><p>(<bold>A</bold>) Analysis of TIGS in 32 cancer types. (<bold>B</bold>) Results of Cox proportional hazards regression analysis using TIGS for all solid cancers. Forest plots showing log<sub>e</sub> hazard ratio (95% confidence interval). Cox p-values are adjusted with the FDR method. p-values less than 0.1 are in bold. The pooled hazard ratios and the p-values were generated using the random effect model. The statistical test for heterogeneity is also shown in the last column. Tumor types are ordered by median TIGS score.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.013</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Pan-cancer distribution pattern of TMB in 9613 TCGA cancer samples.</title><p>(<bold>A</bold>) The distribution of non-synonymous whole-exome mutation counts of 9613 TCGA cancer samples. (<bold>B</bold>) Log<sub>e</sub>-based TMB values show a Gaussian distribution.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>TIGS and pan-cancer ORR to PD-1 inhibition</title><p>Previous studies have shown that TMB can predict pan-cancer ICI ORR (<xref ref-type="bibr" rid="bib48">Yarchoan et al., 2017</xref>). Here, we evaluated and compared the performance of APS, TIGS with TMB in pan-cancer ICI ORR correlation. The ORR for anti–PD-1 or anti–PD-L1 therapy were plotted against the corresponding median APS, TIGS, TMB across multiple cancer types. In an extensive literature search, we identified 25 tumor types or subtypes for which ORR data are available. For each tumor type, we pooled the response data from the largest published studies that evaluated ORR. We included only studies of anti–PD-1 or anti–PD-L1 monotherapy that enrolled at least 10 patients who were not selected for PD-L1 tumor expression. (Identified individual studies and references are available in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>.)</p><p>To calculate TIGS, two different approaches can be applied. In the first approach, the APS and TMB information are obtained from different studies. This approach can include a greater number of different cancer datasets. In a second approach, all APS and TMB information is obtained from the same TCGA datasets, and in this case, fewer cancer types are available for investigation. When using the first approach, in order to calculate TIGS, the median TMB for each tumor type was obtained from a validated comprehensive genomic profiling assay that was performed and provided by Foundation Medicine (<xref ref-type="bibr" rid="bib5">Chalmers et al., 2017</xref>). The APS information for 23 tumor types was calculated on the basis of TCGA datasets, whereas the APS for Merkel cell carcinoma, cutaneous squamous cell carcinoma and small-cell lung cancer were calculated on the basis of GEO microarray datasets. Significant correlations between APS, TMB, TIGS and the ORR were observed (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The correlation coefficients between APS and ORR and between TMB and ORR were 0.42 (p=0.038) and 0.71 (p=6.8e-5), respectively (<xref ref-type="fig" rid="fig4">Figure 4</xref>), suggesting that 18% and 50% of the difference in the ORR across cancer types could be explained by APS and TMB, respectively. The correlation coefficient between TIGS and ORR is 0.78 (p=5.4e-6) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), indicating that 60% of the difference in ORR could be explained by TIGS. These pan-cancer ORR analyses imply that TIGS performs better than TMB or APS in correlations with immunotherapy ORR. When using the second approach for TIGS calculation, TIGS still outperformed both TMB and APS in pan-cancer ORR correlation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.49020.014</object-id><label>Figure 4.</label><caption><title>TIGS and predicted pan-cancer response rates to PD-1 inhibition.</title><p>Correlation between (<bold>A</bold>) APS, (<bold>B</bold>) TMB, (<bold>C</bold>) TIGS and objective response rate (ORR) with anti-PD-1 or anti-PD-L1 therapy in 25 cancer types. Shown are median normalized APS (A), median number of TMB (non-synonymous mutation/MB) in log scale (B) and TIGS in 25 tumor types or subtypes among patients who received inhibitors of PD-1 or PD-L1 (C), as described in published studies for which data regarding the ORR are available. The number of patients who were evaluated for the ORR is shown for each tumor type (size of the circle), along with the number of tumor samples that were analyzed to calculate the APS, TMB or TIGS (degree of shading of the circle).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.49020.016</object-id><label>Figure 4—source data 1.</label><caption><title>List of citations for individual studies used in pooled analysis of objective response rate.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49020-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><object-id pub-id-type="doi">10.7554/eLife.49020.017</object-id><label>Figure 4—source data 2.</label><caption><title>Summary of pooled ORR, median TMB and median APS by tumor type or subtype.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49020-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.015</object-id><label>Figure 4—figure supplement 1.</label><caption><title>TIGS and predicted pan-cancer response rates to PD-1 inhibition.</title><p>Correlation between (<bold>A</bold>) APS, (<bold>B</bold>) TMB, (<bold>C</bold>) TIGS and objective response rate (ORR) with anti-PD-1 or anti-PD-L1 therapy in 18 cancer types. Shown are median normalized APS, median number of TMB (non-synonymous mutation/MB) in log scale and TIGS in 18 TCGA tumor types. The number of patients who were evaluated for the objective response rate is shown for each tumor type (size of the circle), along with the number of tumor samples that were analyzed to calculate the APS, TMB or TIGS (degree of shading of the circle). This analysis is similar to main <xref ref-type="fig" rid="fig4">Figure 4</xref>, except that APS, TMB and TIGA are all calculated for TCGA datasets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>TIGS and prediction of clinical response to ICI</title><p>Compared with TMB and APS, TIGS showed improved correlation with immunotherapy ORR in various types of cancer. Here, we further evaluate the performance of TIGS in predicting ICI clinical response for individual cancer patients. Recently, several prediction biomarkers for immunotherapy response that are based on gene-expression profiling have been reported (<xref ref-type="bibr" rid="bib1">Ayers et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Jiang et al., 2018</xref>). <xref ref-type="bibr" rid="bib1">Ayers et al. (2017)</xref> reported an IFN-γ-related mRNA expression signature that predicts clinical response to PD-1 blockade. <xref ref-type="bibr" rid="bib3">Benci et al. (2019)</xref> recently described two distinct interferon-related gene expression signatures: ISG.RS, which is associated with resistance to ICI, and by contrast, IFNG.GS, which is derived from an IFNG hallmark geneset and associated with response to ICI. <xref ref-type="bibr" rid="bib17">Jiang et al. (2018)</xref> reported a T-cell dysfunction and exclusion gene expression signature (named ‘TIDE’ in the original paper) as a biomarker for cancer immunotherapy response. TIDE outperforms known immunotherapy biomarkers — TMB, PD-L1 expression, and interferon gamma gene expression signature — in predicting the response to immunotherapy in melanoma and lung cancer (<xref ref-type="bibr" rid="bib17">Jiang et al., 2018</xref>). The predictive power of TIGS in ICI clinical response was evaluated and compared with those of TMB and biomarkers based on gene expression profiling using ICI datasets, which contain both TMB and transcriptome data for individual patients. In total, two melanoma datasets (<xref ref-type="bibr" rid="bib15">Hugo et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">Van Allen et al., 2015</xref>) and one urothelial cancer (<xref ref-type="bibr" rid="bib38">Snyder et al., 2017</xref>) dataset were available for this analysis.</p><p>To evaluate performance in predicting clinical response to ICI, we used the receiver operating characteristic (ROC) curve to measure the true-positive rates against the false-positive rates at various thresholds of TMB, TIDE or TIGS values (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>). When compared to the widely used ICI-response biomarker TMB, TIGS consistently achieved better performance in all three ICI datasets (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>). The predictive power of TIGS was comparable to that of TIDE in the two melanoma datasets. However, TIDE failed to predict response to immunotherapy in urothelial cancer, so TIGS showed better performance in the urothelial cancer dataset (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). TIGS also outperforms other immunotherapy biomarkers that are based on gene expression profiling, including IIS, IFNG, ISG.RS, IFNG.GS and CD8, in all three datasets (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The list of genes used to calculate IFNG, ISG.RS, IFNG.GS and CD8 signatures are available <xref ref-type="supplementary-material" rid="fig5sdata1">in Figure 5—source data 1</xref>. Interestingly, APS itself also shows improved or similar prediction power when compared to other gene-expression-profiling-based biomarkers (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). The expression profiles of randomly selected genes (named ‘APSr’ in <xref ref-type="fig" rid="fig5">Figure 5D–F</xref>), which were used as a negative control, failed to predict immunotherapy response in all three datasets.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.49020.018</object-id><label>Figure 5.</label><caption><title>TIGS predicts clinical response to ICI immunotherapy.</title><p>(<bold>A</bold>) ROC curves for the performance of TMB, TIDE and TIGS in predicting anti-CTLA4 Immunotherapy response in 35 melanoma patients (dataset from <xref ref-type="bibr" rid="bib41">Van Allen et al., 2015</xref>). (<bold>B</bold>) ROC curves for the performance of TMB, TIDE and TIGS in predicting anti-PD-1 immunotherapy response in 27 melanoma patients (dataset from <xref ref-type="bibr" rid="bib15">Hugo et al., 2016</xref>). (<bold>C</bold>) ROC curves for the performance of TMB, TIDE and TIGS in predicting anti-PD-L1 immunotherapy response in 22 urothelial cancer patients (dataset from <xref ref-type="bibr" rid="bib38">Snyder et al., 2017</xref>). (<bold>D–F</bold>) AUC values of TMB, TIGS, TIDE, PDL1, immune infiltration score (IIS), interferon gamma gene expression signature (IFNG), CD8, APS and random genes as negative control for APS quantification (APSr) in the <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> dataset (D), the <xref ref-type="bibr" rid="bib15">Hugo et al. (2016)</xref> dataset (E) and the <xref ref-type="bibr" rid="bib38">Snyder et al. (2017)</xref> dataset (F). The performance of a random predictor (AUC = 0.5) is represented by the dashed line. (<bold>G,J,M</bold>) Patients were grouped on the basis of TMB (G), TIGS (J) or TIDE (M) status. The Kaplan–Meier (KM) overall survival curves were compared between TMB-High and TMB-Low (100 patients), between TIGS-High vs TIGS-Low (35 patients) or between TIDE-High and TIDE-Low (37 patients) in the <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> dataset. (<bold>H,K,N</bold>) Patients were grouped on the basis of TMB (<bold>H</bold>), TIGS (K) or TIDE (N) status. The KM overall survival curves were compared between TMB-High and TMB-Low (37 patients), between TIGS-High and TIGS-Low (26 patients) or between TIDE-High and TIDE-Low (26 patients) in the <xref ref-type="bibr" rid="bib15">Hugo et al. (2016)</xref> dataset. (<bold>I,L,O</bold>) Patients were grouped on the basis of TMB (<bold>I</bold>), TIGS (<bold>L</bold>) or TIDE (<bold>O</bold>) status. The KM overall survival curves were compared between TMB-High and TMB-Low (22 patients), TIGS-High and TIGS-Low (22 patients) or TIDE-High and TIDE-Low (25 patients) in the <xref ref-type="bibr" rid="bib38">Snyder et al. (2017)</xref> dataset.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.49020.021</object-id><label>Figure 5—source data 1.</label><caption><title>List of genes in the lists used for CD8, IFNG, ISG.RS and IFNG.GS signature calculation.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49020-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.019</object-id><label>Figure 5—figure supplement 1.</label><caption><title>ROC curves for the performance of APS, CD8, IFNG, IIS, PDL1 and TIGS in predicting immunotherapy response in the <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> melanoma dataset (<bold>A</bold>), the <xref ref-type="bibr" rid="bib15">Hugo et al. (2016)</xref> melanoma dataset (<bold>B</bold>) and the <xref ref-type="bibr" rid="bib38">Snyder et al. (2017)</xref> urothelial cancer dataset (<bold>C</bold>).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49020.020</object-id><label>Figure 5—figure supplement 2.</label><caption><title>APS in predicting the clinical response to immunotherapy.</title><p>Patients were grouped on the basis of APS status. The Kaplan–Meier (KM) overall survival curves were compared between APS-High and APS-Low in the <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> melanoma dataset (<bold>A</bold>), in the <xref ref-type="bibr" rid="bib15">Hugo et al. (2016)</xref> melanoma dataset (<bold>B</bold>), and in the <xref ref-type="bibr" rid="bib38">Snyder et al. (2017)</xref> urothelial cancer dataset (<bold>C</bold>). Log-rank test p-values are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-fig5-figsupp2-v1.tif"/></fig></fig-group><p>In all three available datasets, Kaplan–Meier overall survival curves were further compared in patients with high vs low TIDE, TMB or TIGS level (<xref ref-type="fig" rid="fig5">Figure 5G–O</xref>). Patients with TIGS above the median were defined as ‘TIGS-High’ while the remaining patients were defined as ‘TIGS-Low’. ‘TMB-High’, ‘TMB-Low’, ‘TIGS-High’ and ‘TIGS-Low’ were similarly defined. Comparison of survival curves showed better survival for TMB-High patients than for TMB-Low patients in all three ICI datasets, even though the difference did not reach significance in any of the three datasets, probably because of the limited sample size (<xref ref-type="fig" rid="fig5">Figure 5G–I</xref>). As defined in the original paper (<xref ref-type="bibr" rid="bib17">Jiang et al., 2018</xref>), TIDE-Low indicates low tumor immune dysfunction and low immune escape, and consequently high immunotherapy response. In the <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> melanoma dataset, significantly improved survival was observed in TIDE-Low patients when compared to TIDE-High patients (<xref ref-type="fig" rid="fig5">Figure 5M</xref>). In the urothelial cancer dataset (<xref ref-type="bibr" rid="bib38">Snyder et al., 2017</xref>), TIDE-Low patients did not have the expected immunotherapy response (<xref ref-type="fig" rid="fig5">Figure 5O</xref>). However, TIGS-High patients showed significantly better survival curves than TIGS-Low patients in all three ICI datasets (<xref ref-type="fig" rid="fig5">Figure 5J–L</xref>). These analyses suggest that in all three available datasets, TIGS outperforms TMB and other biomarkers that are based on gene-expression profiling (TIDE, IFNG etc.) in accurately predicting clinical response to immunotherapy and in pan-cancer applicability.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Immunogenicity is an important inherent feature of tumor cells. This feature is determined by the tumor cell itself, and is also influenced by the tumor microenvironment. Two key determinants of tumor immunogenicity are tumor antigenicity and the ability to present such antigenicity. Here, we proposed an initial method to measure the immunogenicity of a tumor. This measured tumor immunogenicity score (TIGS) shows consistently improved correlations with immunotherapy ORR in various types of cancer when compared to TMB. TIGS also shows improved performance in ICI clinical response prediction when compared with TMB and other biomarkers that are based on gene expression profiling (TIDE, interferon gamma signature and so on) in both prediction accuracy and pan-cancer applicability. Furthermore, our tumor-immunogenicity-based biomarker could guide the treatment to transform some ICI-non-responsive tumors into ICI-responsive tumors. Stimulating the APM pathway could enhance tumor immunogenicity, and possibly ICI responsiveness.</p><p>Our study demonstrates that TIGS is an effective biomarker for ICI-response prediction. TIGS capture two key aspects of tumor immunogenicity, antigen presentation and tumor antigenicity, which could be the reason for its improved performance in ICI-response prediction when compared to known biomarkers. Furthermore, our formula for TIGS calculation can point to a new way to transform some ICI-non-responsive tumors into responsive tumors by enhancing the tumor immunogenicity. One approach is to enhance the efficiency of antigen presentation. Our GSEA indicates that interferon signaling is the top gene signature associated with APS-High, and interferon signaling has been reported to influence APM gene expression (<xref ref-type="bibr" rid="bib2">Beatty and Paterson, 2001</xref>; <xref ref-type="bibr" rid="bib16">Ikeda et al., 2002</xref>). We may enhance antigen presentation by stimulating interferon signaling in patients who are initially not responsive to ICI, especially in cancer types that have low APS, such as prostate cancer and breast cancer.</p><p>Our study identified several cancer types in which antigen presentation status makes a significant contribution in ICI response. Breast cancer and prostate cancer have usual TMB but fairly low ICI-response rates, probably because of low APS; renal clear cell carcinoma has good ICI response rate, possibly as a result of high APS. Furthermore, our linear correlation formula — ORR = 21.4 × TIGS – 2.7 (this formula is based on the data in <xref ref-type="fig" rid="fig4">Figure 4C</xref>) — can be used to make hypotheses with respect to the ORR in tumor types for which anti–PD-1 therapy has not been explored. For example, we anticipate a clinically meaningful ORR of 12.3% (95% confidence interval [CI], 8.8% to 15.8%) for uterine corpus endometrial carcinoma (UCEC) on the basis of a median TIGS of 0.7.</p><p>This study reports the first quantification of tumor immunogenicity. Several situations need to be considered for future improvement of this quantification. First, other factors including tumor germline antigen, copy number variation status, tumor purity and intra-tumor heterogeneity should also be considered to enable more accurate measurement of the antigenicity of tumor cells. Second, for quantifying antigen presentation efficiency, APM protein expression and function assessment will be more accurate than APM mRNA expression measurement. Third, other factors that influence TIGS should also be considered, including the function of professional antigen presentation cells (dendritic cells for example) in the immune microenvironment.</p><p>This manuscript primarily focused on the cytosolic or endogenous neoantigen presentation pathway mediated by MHC class I. This does not mean that the potential neoantigen presentation by MHC class II is not important, and further studies are needed to improve the methods for the quantification of antigen presentation in cancer patients. In addition, a sex difference in the predictive power of TMB has been reported recently in lung cancer (<xref ref-type="bibr" rid="bib45">Wang et al., 2019b</xref>; <xref ref-type="bibr" rid="bib46">Wang et al., 2019c</xref>). To explore the potential sex difference in TIGS’s predictive power, we need larger datasets with more patients.</p><p>TIGS is an extension and enhancement of the immunotherapy biomarker TMB. TIGS is tumor cell-based, and is distinct from the recent immunotherapy biomarkers immunophenoscore (<xref ref-type="bibr" rid="bib6">Charoentong et al., 2017</xref>) or T-cell dysfunction and exclusion signature (<xref ref-type="bibr" rid="bib17">Jiang et al., 2018</xref>). Both of these ICI biomarkers are based on tumor immune microenvironment. As a tumor inherent biomarker, TIGS can not only be used for predicting immunotherapy response, but also point ways to manipulate the immunogenicity of tumors, and consequently the response to immunotherapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Pan-cancer clinical, gene expression and mutation data</title><p>The pancan normalized gene-level RNA-Seq data and clinical information for 33 TCGA cohorts were downloaded from UCSC Xena (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/">https://xenabrowser.net/</ext-link>) with R package UCSCXenaTools (<xref ref-type="bibr" rid="bib47">Wang and Liu, 2019a</xref>). Samples with ‘pathologic stage’ 0 or X were filtered out and only ‘sample type’ is ‘Primary Tumor’ (32 cancer types, N = 9109) were saved for further analysis. Pre-compiled, curated somatic mutations (MC3 version) for TCGA cohorts were downloaded by the R package TCGAmutations (<xref ref-type="bibr" rid="bib11">Ellrott et al., 2018</xref>). Microarray gene expression datasets for Merkel cell carcinoma, cutaneous squamous carcinoma and small cell lung cancer were downloaded from the GEO database via R package GEOquery (<xref ref-type="bibr" rid="bib9">Davis and Meltzer, 2007</xref>). Specifically, GSE39612 (<xref ref-type="bibr" rid="bib13">Harms et al., 2013</xref>), GSE22396 (<xref ref-type="bibr" rid="bib29">Paulson et al., 2011</xref>), GSE36150 (<xref ref-type="bibr" rid="bib24">Masterson et al., 2014</xref>), GSE50451 (<xref ref-type="bibr" rid="bib8">Daily et al., 2015</xref>), GSE99316 (<xref ref-type="bibr" rid="bib33">Sato et al., 2013</xref>) were identified and downloaded.</p></sec><sec id="s4-2"><title>Implementation of GSVA</title><p>APM gene expression status and infiltration levels for immune cell types were quantified using the GSVA method implemented in the R package GSVA (<xref ref-type="bibr" rid="bib12">Hänzelmann et al., 2013</xref>). RNA-Seq or microarray datasets were provided as input and output is a near-Gaussian list of decimals that can be used in visualization or downstream statistical analysis. Lists of genes for quantifying immune cell types were as previously described (<xref ref-type="bibr" rid="bib35">Şenbabaoğlu et al., 2016</xref>). Gene lists for APM score and quantification of immune cell type are provided in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p></sec><sec id="s4-3"><title>Calculation of immune infiltration score</title><p>The immune infiltration score (IIS) for a sample was defined as the mean of standardized values for macrophages, DC subsets (total, plasmacytoid, immature, activated), B cells, cytotoxic cells, eosinophils, mast cells, neutrophils, NK cell subsets (total, CD56 bright, CD56 dim), and all T-cell subsets (CD8 T, T helper, T central and effector memory, Th1, Th2, Th17, and Treg cells). In vitro validation with multiplex immunofluorescence, in silico validation using simulated mixing proportions and comparison between CIBERSORT (<xref ref-type="bibr" rid="bib27">Newman et al., 2015</xref>) and IIS have been described previously (<xref ref-type="bibr" rid="bib35">Şenbabaoğlu et al., 2016</xref>). TIMER (<xref ref-type="bibr" rid="bib20">Li et al., 2016</xref>) is another method that can accurately resolve the relative fractions of diverse cell types on the basis of gene expression profiles from complex tissues. To further validate the calculated IIS, we performed TIMER analysis and found that the result of TIMER was highly correlated with the calculated IIS (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></sec><sec id="s4-4"><title>APM score normalization for TIGS calculation</title><p>Original APM scores (APS) from GSVA are in the range of −1 to 1. To calculate TIGS, original APM score from GSVA implementation was rescaled by the minimal and maximal APM score from TCGA Pan-cancer analysis. The formula is<disp-formula id="equ3"><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the minimal APM score among TCGA pan-cancer samples; and <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the maximal APM score among TCGA pan-cancer samples. The normalized APM scores are in the range of 0 to 1. The normalized APS is set to 0 if a loss of function mutation exists in the <italic>B2M</italic> gene.</p></sec><sec id="s4-5"><title>Normalization of TMB data for TIGS calculation</title><p>TMB was defined as the number of non-synonymous alterations per megabase (Mb) of genome examined. As reported previously (<xref ref-type="bibr" rid="bib5">Chalmers et al., 2017</xref>), we used 38 Mb as the estimate of the exome size. For studies reporting mutation number from whole exome sequencing, the normalized TMB = (whole exome non-synonymous mutations)/(38 Mb).</p></sec><sec id="s4-6"><title>TIGS calculation</title><p>We calculated TIGS as following:<disp-formula id="equ4"><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">z</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>The natural logarithm was used here. Notably, some tumors have a TMB level below one mutation/Mb, so to avoid a negative number in quantifying ‘tumor antigenicity’, we added a pseudo count of one to normalized TMB. So the TIGS formula is:<disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>M</mml:mi><mml:mi>B</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>or<disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:mrow><mml:mn>38</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-7"><title>Immunotherapy clinical studies search strategy</title><p>The dataset search strategy for assessment of cancer immunotherapy ORR) assessment has been described previously (<xref ref-type="bibr" rid="bib48">Yarchoan et al., 2017</xref>). We searched MEDLINE (from January 1, 2012 to September 1, 2018), as well as abstracts in the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association for Cancer Research (AACR), to identify clinical studies for anti-PD1 or anti-PDL1 therapy in various tumor types or subtypes. We searched for clinical trials using the following keywords: nivolumab, BMS-936558, pembrolizumab, MK-3475, atezolizumab, MPDL3280A, durvalumab, MEDI4736, avelumab, MSB0010718C, BMS-936559, cemiplimab, and REGN2810. We excluded studies that enrolled fewer than 10 participants, studies that investigated anti-PD-(L)one therapies only in combination with other agents, and studies that selected patients on the basis of PD-L1 expression or other immune-related biomarkers. Of the remaining studies, only the largest published study for each anti-PD-(L)one therapy was included in the final assessment of pooled ORR for each tumor type or subtype. The final identified individual studies are summarized and presented in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. The TMB information for major solid tumor types or subtypes has been described previously (<xref ref-type="bibr" rid="bib5">Chalmers et al., 2017</xref>). The APS of most tumor types or subtypes are based on TCGA RNA-seq data, except those for Merkel cell carcinoma, cutaneous squamous carcinoma and small cell lung cancer, which do not have available TCGA RNA-seq data. For these cancer types, the GEO datasets GSE39612, GSE22396, GSE36150, GSE50451, GSE99316 were used to generate APS. In total, 28 cancer types have both TMB and ORR values, and 25 of them also have transcriptome data that can be used for calculating APS. Therefore, TIGS were calculated for these 25 cancer types which have both TMB and APS information available (<xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). Linear regression models were constructed to correlate ORR with APS, TMB and TIGS for each of the cancer types or subtypes.</p></sec><sec id="s4-8"><title>Collection and analysis of immunotherapy genomics datasets</title><p>To evaluate the power of TIGS to predict clinical response to ICIs, we searched PubMed for ICI clinical studies for which TMB and gene transcriptome information was available for individual patients. In total, three datasets were identified after this search. The <xref ref-type="bibr" rid="bib41">Van Allen et al. (2015)</xref> dataset was downloaded from the supplementary files of reference (<xref ref-type="bibr" rid="bib41">Van Allen et al., 2015</xref>). This dataset related to CTLA-4 blockade in metastatic melanoma, and defined ‘clinical benefit’ using a composite end point of complete response or partial response to CTLA-4 blockade as assessed by RECIST criteria or stable disease by RECIST criteria with overall survival greater than 1 year, ‘no clinical benefit’ was defined as progressive disease by RECIST criteria or stable disease with overall survival less than 1 year (<xref ref-type="bibr" rid="bib41">Van Allen et al., 2015</xref>). The <xref ref-type="bibr" rid="bib15">Hugo et al. (2016)</xref> dataset was downloaded from the supplementary files of reference (<xref ref-type="bibr" rid="bib15">Hugo et al., 2016</xref>). This dataset related to anti-PD-1therapy in metastatic melanoma: responding tumors were derived from patients who have complete or partial responses or stable disease in response to anti-PD-1 therapy; non-responding tumors were derived from patients who had progressive disease (<xref ref-type="bibr" rid="bib15">Hugo et al., 2016</xref>). The <xref ref-type="bibr" rid="bib38">Snyder et al. (2017)</xref> dataset (<xref ref-type="bibr" rid="bib38">Snyder et al., 2017</xref>) was downloaded from <ext-link ext-link-type="uri" xlink:href="https://github.com/hammerlab/multi-omic-urothelial-anti-pdl1">https://github.com/hammerlab/multi-omic-urothelial-anti-pdl1</ext-link>. This dataset related to PD-L1 blockade in urothelial cancer: durable clinical benefit was defined as progression-free survival &gt;6 months (<xref ref-type="bibr" rid="bib38">Snyder et al., 2017</xref>). RNA-Seq data were used to calculate the APS for each patient. Only patients for whom both APS and TMB value were available were used to calculate the TIGS. The median of TMB or TIGS was used as the threshold to separate the TMB-High and TMB-Low groups or the TIGS-High and TIGS-Low group in Kaplan-Meier overall survival curve analysis.</p></sec><sec id="s4-9"><title>Performance comparison on predicting immunotherapy response</title><p>The immunotherapy clinical response prediction performance of TIGS and APS have been compared with those of the following biomarkers: TMB, TIDE, IFNG, IFNG.GS, ISG.RS, PDL1, IIS, and CD8. The TIDE score was calculated using online software that is available on the website <ext-link ext-link-type="uri" xlink:href="http://tide.dfci.harvard.edu">http://tide.dfci.harvard.edu</ext-link>. We followed the instructions on the website to generate input data for TIDE score calculation and exported the results to CSV files. The TIDE scores in the result files were used to predict response. The calculation of scores for the gene-expression-profiling-based biomarkers (i.e. IFNG, CD8, and PDL1) has been described by <xref ref-type="bibr" rid="bib17">Jiang et al. (2018)</xref>. The average expression values among all members defined by the original publications were used to quantify each biomarker. The interferon gamma gene expression signature (<xref ref-type="bibr" rid="bib1">Ayers et al., 2017</xref>) (IFNG) used genes <italic>IFNG</italic>, <italic>STAT1</italic>, <italic>IDO1</italic>, <italic>CXCL10</italic>, <italic>CXCL9</italic>, and <italic>HLA-DRA</italic>. The calculation of IFNG.GS and ISG.RS scores were previously described in <xref ref-type="bibr" rid="bib3">Benci et al. (2019)</xref>. CD8 used genes <italic>CD8A</italic> and <italic>CD8B</italic>. PDL1 used gene <italic>CD274</italic>. As a negative control, we performed GSVA with 18 randomly selected genes, and the resulting score was named ‘APSr’ here. This GSVA with random genes was repeated for 100 times, and APSr were used to predict immunotherapy response. The average AUC of these 100 APSr is shown.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Univariate cox analysis was performed by R package survival. P values were adjusted using the FDR method, and FDR &lt; 0.1 is considered statistically significant. Hazard ratios and their 95% confidence intervals for TCGA cancer types were collected and used for meta-analysis with the random effect model in the R package metafor (<xref ref-type="bibr" rid="bib42">Viechtbauer, 2010</xref>). The receiver operator characteristic (ROC) curve was generated by plotting the rate of response at various threshold settings of TMB, TIDE or TIGS within the R package pROC (<xref ref-type="bibr" rid="bib32">Robin et al., 2011</xref>). The area under the curve (AUC) was reported for each analysis. On the basis of the median of TMB, TIDE or TIGS, we separated patients into High and Low group in the survival analysis. Keplan-Meier curves of overall survival were thus plotted with log-rank test p-value in the R package ggpubr. For GSEA enrichment analysis, we compared samples that had APS above the median with those that had APS below the median across TCGA tumor types using the limma package (<xref ref-type="bibr" rid="bib30">Ritchie et al., 2015</xref>). Genes with p-value &lt; 0.01 and FDR &lt; 0.05 were ranked by logFC from top to bottom and then inputted into the GSEA function of the R package clusterProfiler (<xref ref-type="bibr" rid="bib49">Yu et al., 2012</xref>) with custom gene sets downloaded from Molecular Signature Database v6.2 (<xref ref-type="bibr" rid="bib21">Liberzon et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Subramanian et al., 2005</xref>). Normalized enrichment score (NES) was used to rank the differentially enriched gene sets. Correlation analysis was performed using the spearman method. All reported p-values are two-tailed, and for all analyses, p&lt;=0.05 is considered statistically significant, unless otherwise specified. Statistical analyses were performed using R (version 3.6.0).</p></sec><sec id="s4-11"><title>Data availability</title><p>All of the code and data used to generate the figures are freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/XSLiuLab/tumor-immunogenicity-score">https://github.com/XSLiuLab/tumor-immunogenicity-score</ext-link> (<xref ref-type="bibr" rid="bib44">Wang, 2019</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/tumor-immunogenicity-score">https://github.com/elifesciences-publications/tumor-immunogenicity-score</ext-link>). Analyses can be read online at <ext-link ext-link-type="uri" xlink:href="https://xsliulab.github.io/tumor-immunogenicity-score/">https://xsliulab.github.io/tumor-immunogenicity-score/</ext-link>. Source data files have been provided for <xref ref-type="fig" rid="fig1">Figures 1</xref>, <xref ref-type="fig" rid="fig2">2</xref>, <xref ref-type="fig" rid="fig4">4</xref> and <xref ref-type="fig" rid="fig5">5</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the authors and participating patients of the immunotherapy publications for providing the data used for this analysis. Our gratitude is also extended to the TCGA project for making cancer genomics data available for analysis. We thank Raymond Shuter for editing the text. Thanks also to the ShanghaiTech University High Performance Computing Public Service Platform for providing computing services. Thanks also to other members of Liu lab for helpful discussions.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.49020.022</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-49020-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All the code and data used to generate the figures are freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/XSLiuLab/tumor-immunogenicity-score">https://github.com/XSLiuLab/tumor-immunogenicity-score</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/tumor-immunogenicity-score">https://github.com/elifesciences-publications/tumor-immunogenicity-score</ext-link>). Analyses can be read online at <ext-link ext-link-type="uri" xlink:href="https://xsliulab.github.io/tumor-immunogenicity-score/">https://xsliulab.github.io/tumor-immunogenicity-score/</ext-link>. Source data files have been provided for Figures 1, 2, 4 and 5.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>P</given-names></name><name><surname>Bichakjian</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Distinct gene expression profiles of viral- and non-viral associated Merkel cell carcinoma revealed by transcriptome analysis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39612">GSE39612</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>KG</given-names></name><name><surname>Iyer</surname><given-names>JG</given-names></name><name><surname>Schelter</surname><given-names>J</given-names></name><name><surname>Cleary</surname><given-names>MA</given-names></name><name><surname>Hardwick</surname><given-names>J</given-names></name><name><surname>Nghiem</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Gene expression analysis of Merkel Cell Carcinoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22396">GSE22396</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Masterson</surname><given-names>L</given-names></name><name><surname>Thibodeau</surname><given-names>BJ</given-names></name><name><surname>Fortier</surname><given-names>LE</given-names></name><name><surname>Geddes</surname><given-names>TJ</given-names></name><name><surname>Pruetz</surname><given-names>BL</given-names></name><name><surname>Keidan</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>Gene expression changes associated with prognosis of Merkel cell carcinoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36150">GSE36150</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Brownell</surname><given-names>I</given-names></name><name><surname>Daily</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Microarray analysis of Merkel cell carcinoma (MCC) tumors, small cell lung cancer (SCLC) tumors, and MCC cell lines</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50451">GSE50451</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Kaneda</surname><given-names>A</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Isagawa</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nukiwa</surname><given-names>T</given-names></name><name><surname>Marquez</surname><given-names>VE</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Ichinose</surname><given-names>M</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Gene repression and ChIP-seq in Human Small Cell Lung Cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99316">GSE99316</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname> <given-names>M</given-names></name><name><surname>Lunceford</surname> <given-names>J</given-names></name><name><surname>Nebozhyn</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>E</given-names></name><name><surname>Loboda</surname> <given-names>A</given-names></name><name><surname>Kaufman</surname> <given-names>DR</given-names></name><name><surname>Albright</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>JD</given-names></name><name><surname>Kang</surname> <given-names>SP</given-names></name><name><surname>Shankaran</surname> <given-names>V</given-names></name><name><surname>Piha-Paul</surname> <given-names>SA</given-names></name><name><surname>Yearley</surname> <given-names>J</given-names></name><name><surname>Seiwert</surname> <given-names>TY</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>2930</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname> <given-names>GL</given-names></name><name><surname>Paterson</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of tumor growth by IFN-gamma in Cancer immunotherapy</article-title><source>Immunologic Research</source><volume>24</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1385/IR:24:2:201</pub-id><pub-id pub-id-type="pmid">11594457</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benci</surname> <given-names>JL</given-names></name><name><surname>Johnson</surname> <given-names>LR</given-names></name><name><surname>Choa</surname> <given-names>R</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Qiu</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Ye</surname> <given-names>D</given-names></name><name><surname>Nathanson</surname> <given-names>KL</given-names></name><name><surname>June</surname> <given-names>CH</given-names></name><name><surname>Wherry</surname> <given-names>EJ</given-names></name><name><surname>Zhang</surname> <given-names>NR</given-names></name><name><surname>Ishwaran</surname> <given-names>H</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Wolchok</surname> <given-names>JD</given-names></name><name><surname>Kambayashi</surname> <given-names>T</given-names></name><name><surname>Minn</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Opposing functions of interferon coordinate adaptive and innate immune responses to Cancer immune checkpoint blockade</article-title><source>Cell</source><volume>178</volume><fpage>933</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.07.019</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blankenstein</surname> <given-names>T</given-names></name><name><surname>Coulie</surname> <given-names>PG</given-names></name><name><surname>Gilboa</surname> <given-names>E</given-names></name><name><surname>Jaffee</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The determinants of tumour immunogenicity</article-title><source>Nature Reviews Cancer</source><volume>12</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/nrc3246</pub-id><pub-id pub-id-type="pmid">22378190</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname> <given-names>ZR</given-names></name><name><surname>Connelly</surname> <given-names>CF</given-names></name><name><surname>Fabrizio</surname> <given-names>D</given-names></name><name><surname>Gay</surname> <given-names>L</given-names></name><name><surname>Ali</surname> <given-names>SM</given-names></name><name><surname>Ennis</surname> <given-names>R</given-names></name><name><surname>Schrock</surname> <given-names>A</given-names></name><name><surname>Campbell</surname> <given-names>B</given-names></name><name><surname>Shlien</surname> <given-names>A</given-names></name><name><surname>Chmielecki</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>F</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Tabori</surname> <given-names>U</given-names></name><name><surname>Kennedy</surname> <given-names>M</given-names></name><name><surname>Lieber</surname> <given-names>DS</given-names></name><name><surname>Roels</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>J</given-names></name><name><surname>Otto</surname> <given-names>GA</given-names></name><name><surname>Ross</surname> <given-names>JS</given-names></name><name><surname>Garraway</surname> <given-names>L</given-names></name><name><surname>Miller</surname> <given-names>VA</given-names></name><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>Frampton</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Analysis of 100,000 human Cancer genomes reveals the landscape of tumor mutational burden</article-title><source>Genome Medicine</source><volume>9</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-017-0424-2</pub-id><pub-id pub-id-type="pmid">28420421</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charoentong</surname> <given-names>P</given-names></name><name><surname>Finotello</surname> <given-names>F</given-names></name><name><surname>Angelova</surname> <given-names>M</given-names></name><name><surname>Mayer</surname> <given-names>C</given-names></name><name><surname>Efremova</surname> <given-names>M</given-names></name><name><surname>Rieder</surname> <given-names>D</given-names></name><name><surname>Hackl</surname> <given-names>H</given-names></name><name><surname>Trajanoski</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pan-cancer immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint blockade</article-title><source>Cell Reports</source><volume>18</volume><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.019</pub-id><pub-id pub-id-type="pmid">28052254</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowell</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>LGT</given-names></name><name><surname>Grigg</surname> <given-names>CM</given-names></name><name><surname>Weber</surname> <given-names>JK</given-names></name><name><surname>Samstein</surname> <given-names>RM</given-names></name><name><surname>Makarov</surname> <given-names>V</given-names></name><name><surname>Kuo</surname> <given-names>F</given-names></name><name><surname>Kendall</surname> <given-names>SM</given-names></name><name><surname>Requena</surname> <given-names>D</given-names></name><name><surname>Riaz</surname> <given-names>N</given-names></name><name><surname>Greenbaum</surname> <given-names>B</given-names></name><name><surname>Carroll</surname> <given-names>J</given-names></name><name><surname>Garon</surname> <given-names>E</given-names></name><name><surname>Hyman</surname> <given-names>DM</given-names></name><name><surname>Zehir</surname> <given-names>A</given-names></name><name><surname>Solit</surname> <given-names>D</given-names></name><name><surname>Berger</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>R</given-names></name><name><surname>Rizvi</surname> <given-names>NA</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Patient HLA class I genotype influences Cancer response to checkpoint blockade immunotherapy</article-title><source>Science</source><volume>359</volume><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1126/science.aao4572</pub-id><pub-id pub-id-type="pmid">29217585</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daily</surname> <given-names>K</given-names></name><name><surname>Coxon</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>JS</given-names></name><name><surname>Lee</surname> <given-names>CR</given-names></name><name><surname>Coit</surname> <given-names>DG</given-names></name><name><surname>Busam</surname> <given-names>KJ</given-names></name><name><surname>Brownell</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Assessment of Cancer cell line representativeness using microarrays for merkel cell carcinoma</article-title><source>Journal of Investigative Dermatology</source><volume>135</volume><fpage>1138</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.518</pub-id><pub-id pub-id-type="pmid">25521454</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>S</given-names></name><name><surname>Meltzer</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>GEOquery: a bridge between the gene expression omnibus (GEO) and BioConductor</article-title><source>Bioinformatics</source><volume>23</volume><fpage>1846</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm254</pub-id><pub-id pub-id-type="pmid">17496320</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davoli</surname> <given-names>T</given-names></name><name><surname>Uno</surname> <given-names>H</given-names></name><name><surname>Wooten</surname> <given-names>EC</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy</article-title><source>Science</source><volume>355</volume><elocation-id>eaaf8399</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaf8399</pub-id><pub-id pub-id-type="pmid">28104840</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellrott</surname> <given-names>K</given-names></name><name><surname>Bailey</surname> <given-names>MH</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Covington</surname> <given-names>KR</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Hess</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Chiotti</surname> <given-names>KE</given-names></name><name><surname>McLellan</surname> <given-names>M</given-names></name><name><surname>Sofia</surname> <given-names>HJ</given-names></name><name><surname>Hutter</surname> <given-names>C</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Wheeler</surname> <given-names>D</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Caesar-Johnson</surname> <given-names>SJ</given-names></name><name><surname>Demchok</surname> <given-names>JA</given-names></name><name><surname>Felau</surname> <given-names>I</given-names></name><name><surname>Kasapi</surname> <given-names>M</given-names></name><name><surname>Ferguson</surname> <given-names>ML</given-names></name><name><surname>Hutter</surname> <given-names>CM</given-names></name><name><surname>Sofia</surname> <given-names>HJ</given-names></name><name><surname>Tarnuzzer</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zenklusen</surname> <given-names>JC</given-names></name><name><surname>Zhang</surname> <given-names>Jiashan (Julia)</given-names></name><name><surname>Chudamani</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lolla</surname> <given-names>L</given-names></name><name><surname>Naresh</surname> <given-names>R</given-names></name><name><surname>Pihl</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Cho</surname> <given-names>J</given-names></name><name><surname>DeFreitas</surname> <given-names>T</given-names></name><name><surname>Frazer</surname> <given-names>S</given-names></name><name><surname>Gehlenborg</surname> <given-names>N</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Heiman</surname> <given-names>DI</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Lin</surname> <given-names>P</given-names></name><name><surname>Meier</surname> <given-names>S</given-names></name><name><surname>Noble</surname> <given-names>MS</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Bernard</surname> <given-names>B</given-names></name><name><surname>Chambwe</surname> <given-names>N</given-names></name><name><surname>Dhankani</surname> <given-names>V</given-names></name><name><surname>Knijnenburg</surname> <given-names>T</given-names></name><name><surname>Kramer</surname> <given-names>R</given-names></name><name><surname>Leinonen</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Reynolds</surname> <given-names>S</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><name><surname>Thorsson</surname> <given-names>V</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Broom</surname> <given-names>BM</given-names></name><name><surname>Hegde</surname> <given-names>AM</given-names></name><name><surname>Ju</surname> <given-names>Z</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Korkut</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Ling</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Ng</surname> <given-names>K-S</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Ryan</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Abeshouse</surname> <given-names>A</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Chakravarty</surname> <given-names>D</given-names></name><name><surname>Chatila</surname> <given-names>WK</given-names></name><name><surname>de Bruijn</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Gross</surname> <given-names>BE</given-names></name><name><surname>Heins</surname> <given-names>ZJ</given-names></name><name><surname>Kundra</surname> <given-names>R</given-names></name><name><surname>La</surname> <given-names>K</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Luna</surname> <given-names>A</given-names></name><name><surname>Nissan</surname> <given-names>MG</given-names></name><name><surname>Ochoa</surname> <given-names>A</given-names></name><name><surname>Phillips</surname> <given-names>SM</given-names></name><name><surname>Reznik</surname> <given-names>E</given-names></name><name><surname>Sanchez-Vega</surname> <given-names>F</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sheridan</surname> <given-names>R</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Taylor</surname> <given-names>BS</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Anur</surname> <given-names>P</given-names></name><name><surname>Peto</surname> <given-names>M</given-names></name><name><surname>Spellman</surname> <given-names>P</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Wong</surname> <given-names>CK</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Hayes</surname> <given-names>DN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines</article-title><source>Cell Systems</source><volume>6</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.03.002</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hänzelmann</surname> <given-names>S</given-names></name><name><surname>Castelo</surname> <given-names>R</given-names></name><name><surname>Guinney</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id><pub-id pub-id-type="pmid">23323831</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname> <given-names>PW</given-names></name><name><surname>Patel</surname> <given-names>RM</given-names></name><name><surname>Verhaegen</surname> <given-names>ME</given-names></name><name><surname>Giordano</surname> <given-names>TJ</given-names></name><name><surname>Nash</surname> <given-names>KT</given-names></name><name><surname>Johnson</surname> <given-names>CN</given-names></name><name><surname>Daignault</surname> <given-names>S</given-names></name><name><surname>Thomas</surname> <given-names>DG</given-names></name><name><surname>Gudjonsson</surname> <given-names>JE</given-names></name><name><surname>Elder</surname> <given-names>JT</given-names></name><name><surname>Dlugosz</surname> <given-names>AA</given-names></name><name><surname>Johnson</surname> <given-names>TM</given-names></name><name><surname>Fullen</surname> <given-names>DR</given-names></name><name><surname>Bichakjian</surname> <given-names>CK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis</article-title><source>Journal of Investigative Dermatology</source><volume>133</volume><fpage>936</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.445</pub-id><pub-id pub-id-type="pmid">23223137</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname> <given-names>RS</given-names></name><name><surname>Soria</surname> <given-names>JC</given-names></name><name><surname>Kowanetz</surname> <given-names>M</given-names></name><name><surname>Fine</surname> <given-names>GD</given-names></name><name><surname>Hamid</surname> <given-names>O</given-names></name><name><surname>Gordon</surname> <given-names>MS</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>McDermott</surname> <given-names>DF</given-names></name><name><surname>Powderly</surname> <given-names>JD</given-names></name><name><surname>Gettinger</surname> <given-names>SN</given-names></name><name><surname>Kohrt</surname> <given-names>HE</given-names></name><name><surname>Horn</surname> <given-names>L</given-names></name><name><surname>Lawrence</surname> <given-names>DP</given-names></name><name><surname>Rost</surname> <given-names>S</given-names></name><name><surname>Leabman</surname> <given-names>M</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Mokatrin</surname> <given-names>A</given-names></name><name><surname>Koeppen</surname> <given-names>H</given-names></name><name><surname>Hegde</surname> <given-names>PS</given-names></name><name><surname>Mellman</surname> <given-names>I</given-names></name><name><surname>Chen</surname> <given-names>DS</given-names></name><name><surname>Hodi</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in Cancer patients</article-title><source>Nature</source><volume>515</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nature14011</pub-id><pub-id pub-id-type="pmid">25428504</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Moreno</surname> <given-names>BH</given-names></name><name><surname>Hu-Lieskovan</surname> <given-names>S</given-names></name><name><surname>Berent-Maoz</surname> <given-names>B</given-names></name><name><surname>Pang</surname> <given-names>J</given-names></name><name><surname>Chmielowski</surname> <given-names>B</given-names></name><name><surname>Cherry</surname> <given-names>G</given-names></name><name><surname>Seja</surname> <given-names>E</given-names></name><name><surname>Lomeli</surname> <given-names>S</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Kelley</surname> <given-names>MC</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Johnson</surname> <given-names>DB</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma</article-title><source>Cell</source><volume>165</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.02.065</pub-id><pub-id pub-id-type="pmid">26997480</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname> <given-names>H</given-names></name><name><surname>Old</surname> <given-names>LJ</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The roles of ifnγ in protection against tumor development and Cancer immunoediting</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>13</volume><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(01)00038-7</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Gu</surname> <given-names>S</given-names></name><name><surname>Pan</surname> <given-names>D</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Sahu</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Traugh</surname> <given-names>N</given-names></name><name><surname>Bu</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Freeman</surname> <given-names>GJ</given-names></name><name><surname>Brown</surname> <given-names>MA</given-names></name><name><surname>Wucherpfennig</surname> <given-names>KW</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Signatures of T cell dysfunction and exclusion predict Cancer immunotherapy response</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1550</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0136-1</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname> <given-names>DT</given-names></name><name><surname>Uram</surname> <given-names>JN</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Bartlett</surname> <given-names>BR</given-names></name><name><surname>Kemberling</surname> <given-names>H</given-names></name><name><surname>Eyring</surname> <given-names>AD</given-names></name><name><surname>Skora</surname> <given-names>AD</given-names></name><name><surname>Luber</surname> <given-names>BS</given-names></name><name><surname>Azad</surname> <given-names>NS</given-names></name><name><surname>Laheru</surname> <given-names>D</given-names></name><name><surname>Biedrzycki</surname> <given-names>B</given-names></name><name><surname>Donehower</surname> <given-names>RC</given-names></name><name><surname>Zaheer</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>GA</given-names></name><name><surname>Crocenzi</surname> <given-names>TS</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Duffy</surname> <given-names>SM</given-names></name><name><surname>Goldberg</surname> <given-names>RM</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name><name><surname>Koshiji</surname> <given-names>M</given-names></name><name><surname>Bhaijee</surname> <given-names>F</given-names></name><name><surname>Huebner</surname> <given-names>T</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Cuka</surname> <given-names>N</given-names></name><name><surname>Pardoll</surname> <given-names>DM</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Cornish</surname> <given-names>TC</given-names></name><name><surname>Taube</surname> <given-names>JM</given-names></name><name><surname>Anders</surname> <given-names>RA</given-names></name><name><surname>Eshleman</surname> <given-names>JR</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PD-1 blockade in tumors with Mismatch-Repair deficiency</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname> <given-names>P</given-names></name><name><surname>Shin</surname> <given-names>EC</given-names></name><name><surname>Perosa</surname> <given-names>F</given-names></name><name><surname>Vacca</surname> <given-names>A</given-names></name><name><surname>Dammacco</surname> <given-names>F</given-names></name><name><surname>Racanelli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>105</volume><fpage>1172</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1093/jnci/djt184</pub-id><pub-id pub-id-type="pmid">23852952</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Severson</surname> <given-names>E</given-names></name><name><surname>Pignon</surname> <given-names>JC</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Novak</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Aster</surname> <given-names>JC</given-names></name><name><surname>Rodig</surname> <given-names>S</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Comprehensive analyses of tumor immunity: implications for Cancer immunotherapy</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1028-7</pub-id><pub-id pub-id-type="pmid">27549193</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname> <given-names>A</given-names></name><name><surname>Birger</surname> <given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name><name><surname>Ghandi</surname> <given-names>M</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marty</surname> <given-names>R</given-names></name><name><surname>Kaabinejadian</surname> <given-names>S</given-names></name><name><surname>Rossell</surname> <given-names>D</given-names></name><name><surname>Slifker</surname> <given-names>MJ</given-names></name><name><surname>van de Haar</surname> <given-names>J</given-names></name><name><surname>Engin</surname> <given-names>HB</given-names></name><name><surname>de Prisco</surname> <given-names>N</given-names></name><name><surname>Ideker</surname> <given-names>T</given-names></name><name><surname>Hildebrand</surname> <given-names>WH</given-names></name><name><surname>Font-Burgada</surname> <given-names>J</given-names></name><name><surname>Carter</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MHC-I genotype restricts the oncogenic mutational landscape</article-title><source>Cell</source><volume>171</volume><fpage>1272</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.050</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marty Pyke</surname> <given-names>R</given-names></name><name><surname>Thompson</surname> <given-names>WK</given-names></name><name><surname>Salem</surname> <given-names>RM</given-names></name><name><surname>Font-Burgada</surname> <given-names>J</given-names></name><name><surname>Zanetti</surname> <given-names>M</given-names></name><name><surname>Carter</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evolutionary pressure against MHC class II binding Cancer mutations</article-title><source>Cell</source><volume>175</volume><fpage>416</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.08.048</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masterson</surname> <given-names>L</given-names></name><name><surname>Thibodeau</surname> <given-names>BJ</given-names></name><name><surname>Fortier</surname> <given-names>LE</given-names></name><name><surname>Geddes</surname> <given-names>TJ</given-names></name><name><surname>Pruetz</surname> <given-names>BL</given-names></name><name><surname>Malhotra</surname> <given-names>R</given-names></name><name><surname>Keidan</surname> <given-names>R</given-names></name><name><surname>Wilson</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gene expression differences predict treatment outcome of merkel cell carcinoma patients</article-title><source>Journal of Skin Cancer</source><volume>2014</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2014/596459</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellman</surname> <given-names>I</given-names></name><name><surname>Steinman</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Dendritic cells: specialized and regulated antigen processing machines</article-title><source>Cell</source><volume>106</volume><fpage>255</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00449-4</pub-id><pub-id pub-id-type="pmid">11509172</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Margolis</surname> <given-names>CA</given-names></name><name><surname>Vokes</surname> <given-names>NI</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Taylor-Weiner</surname> <given-names>A</given-names></name><name><surname>Wankowicz</surname> <given-names>SM</given-names></name><name><surname>Adeegbe</surname> <given-names>D</given-names></name><name><surname>Keliher</surname> <given-names>D</given-names></name><name><surname>Schilling</surname> <given-names>B</given-names></name><name><surname>Tracy</surname> <given-names>A</given-names></name><name><surname>Manos</surname> <given-names>M</given-names></name><name><surname>Chau</surname> <given-names>NG</given-names></name><name><surname>Hanna</surname> <given-names>GJ</given-names></name><name><surname>Polak</surname> <given-names>P</given-names></name><name><surname>Rodig</surname> <given-names>SJ</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Sholl</surname> <given-names>LM</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name><name><surname>Haddad</surname> <given-names>RI</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name><name><surname>Barbie</surname> <given-names>DA</given-names></name><name><surname>Haq</surname> <given-names>R</given-names></name><name><surname>Awad</surname> <given-names>MM</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Hodi</surname> <given-names>FS</given-names></name><name><surname>Bellmunt</surname> <given-names>J</given-names></name><name><surname>Wong</surname> <given-names>KK</given-names></name><name><surname>Hammerman</surname> <given-names>P</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors</article-title><source>Nature Genetics</source><volume>50</volume><fpage>1271</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0200-2</pub-id><pub-id pub-id-type="pmid">30150660</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>AM</given-names></name><name><surname>Liu</surname> <given-names>CL</given-names></name><name><surname>Green</surname> <given-names>MR</given-names></name><name><surname>Gentles</surname> <given-names>AJ</given-names></name><name><surname>Feng</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Hoang</surname> <given-names>CD</given-names></name><name><surname>Diehn</surname> <given-names>M</given-names></name><name><surname>Alizadeh</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title><source>Nature Methods</source><volume>12</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id><pub-id pub-id-type="pmid">25822800</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname> <given-names>M</given-names></name><name><surname>Ramaiya</surname> <given-names>NH</given-names></name><name><surname>Hatabu</surname> <given-names>H</given-names></name><name><surname>Hodi</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monitoring immune-checkpoint blockade: response evaluation and biomarker development</article-title><source>Nature Reviews Clinical Oncology</source><volume>14</volume><fpage>655</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.88</pub-id><pub-id pub-id-type="pmid">28653677</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname> <given-names>KG</given-names></name><name><surname>Iyer</surname> <given-names>JG</given-names></name><name><surname>Tegeder</surname> <given-names>AR</given-names></name><name><surname>Thibodeau</surname> <given-names>R</given-names></name><name><surname>Schelter</surname> <given-names>J</given-names></name><name><surname>Koba</surname> <given-names>S</given-names></name><name><surname>Schrama</surname> <given-names>D</given-names></name><name><surname>Simonson</surname> <given-names>WT</given-names></name><name><surname>Lemos</surname> <given-names>BD</given-names></name><name><surname>Byrd</surname> <given-names>DR</given-names></name><name><surname>Koelle</surname> <given-names>DM</given-names></name><name><surname>Galloway</surname> <given-names>DA</given-names></name><name><surname>Leonard</surname> <given-names>JH</given-names></name><name><surname>Madeleine</surname> <given-names>MM</given-names></name><name><surname>Argenyi</surname> <given-names>ZB</given-names></name><name><surname>Disis</surname> <given-names>ML</given-names></name><name><surname>Becker</surname> <given-names>JC</given-names></name><name><surname>Cleary</surname> <given-names>MA</given-names></name><name><surname>Nghiem</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival</article-title><source>Journal of Clinical Oncology</source><volume>29</volume><fpage>1539</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.6308</pub-id><pub-id pub-id-type="pmid">21422430</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname> <given-names>ME</given-names></name><name><surname>Phipson</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Law</surname> <given-names>CW</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname> <given-names>NA</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Kvistborg</surname> <given-names>P</given-names></name><name><surname>Makarov</surname> <given-names>V</given-names></name><name><surname>Havel</surname> <given-names>JJ</given-names></name><name><surname>Lee</surname> <given-names>W</given-names></name><name><surname>Yuan</surname> <given-names>J</given-names></name><name><surname>Wong</surname> <given-names>P</given-names></name><name><surname>Ho</surname> <given-names>TS</given-names></name><name><surname>Miller</surname> <given-names>ML</given-names></name><name><surname>Rekhtman</surname> <given-names>N</given-names></name><name><surname>Moreira</surname> <given-names>AL</given-names></name><name><surname>Ibrahim</surname> <given-names>F</given-names></name><name><surname>Bruggeman</surname> <given-names>C</given-names></name><name><surname>Gasmi</surname> <given-names>B</given-names></name><name><surname>Zappasodi</surname> <given-names>R</given-names></name><name><surname>Maeda</surname> <given-names>Y</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Garon</surname> <given-names>EB</given-names></name><name><surname>Merghoub</surname> <given-names>T</given-names></name><name><surname>Wolchok</surname> <given-names>JD</given-names></name><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung Cancer</article-title><source>Science</source><volume>348</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><pub-id pub-id-type="pmid">25765070</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname> <given-names>X</given-names></name><name><surname>Turck</surname> <given-names>N</given-names></name><name><surname>Hainard</surname> <given-names>A</given-names></name><name><surname>Tiberti</surname> <given-names>N</given-names></name><name><surname>Lisacek</surname> <given-names>F</given-names></name><name><surname>Sanchez</surname> <given-names>JC</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="pmid">21414208</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>T</given-names></name><name><surname>Kaneda</surname> <given-names>A</given-names></name><name><surname>Tsuji</surname> <given-names>S</given-names></name><name><surname>Isagawa</surname> <given-names>T</given-names></name><name><surname>Yamamoto</surname> <given-names>S</given-names></name><name><surname>Fujita</surname> <given-names>T</given-names></name><name><surname>Yamanaka</surname> <given-names>R</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Nukiwa</surname> <given-names>T</given-names></name><name><surname>Marquez</surname> <given-names>VE</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name><name><surname>Ichinose</surname> <given-names>M</given-names></name><name><surname>Aburatani</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung Cancer</article-title><source>Scientific Reports</source><volume>3</volume><elocation-id>1911</elocation-id><pub-id pub-id-type="doi">10.1038/srep01911</pub-id><pub-id pub-id-type="pmid">23714854</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Schreiber</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Şenbabaoğlu</surname> <given-names>Y</given-names></name><name><surname>Gejman</surname> <given-names>RS</given-names></name><name><surname>Winer</surname> <given-names>AG</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>de Velasco</surname> <given-names>G</given-names></name><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Ostrovnaya</surname> <given-names>I</given-names></name><name><surname>Drill</surname> <given-names>E</given-names></name><name><surname>Luna</surname> <given-names>A</given-names></name><name><surname>Weinhold</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>W</given-names></name><name><surname>Manley</surname> <given-names>BJ</given-names></name><name><surname>Khalil</surname> <given-names>DN</given-names></name><name><surname>Kaffenberger</surname> <given-names>SD</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Danilova</surname> <given-names>L</given-names></name><name><surname>Voss</surname> <given-names>MH</given-names></name><name><surname>Coleman</surname> <given-names>JA</given-names></name><name><surname>Russo</surname> <given-names>P</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name><name><surname>Cheng</surname> <given-names>EH</given-names></name><name><surname>Scheinberg</surname> <given-names>DA</given-names></name><name><surname>Li</surname> <given-names>MO</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Hakimi</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>231</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1092-z</pub-id><pub-id pub-id-type="pmid">27855702</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukuya</surname> <given-names>T</given-names></name><name><surname>Carbone</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Predictive markers for the efficacy of Anti-PD-1/PD-L1 antibodies in lung Cancer</article-title><source>Journal of Thoracic Oncology</source><volume>11</volume><fpage>976</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.02.015</pub-id><pub-id pub-id-type="pmid">26944305</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Makarov</surname> <given-names>V</given-names></name><name><surname>Merghoub</surname> <given-names>T</given-names></name><name><surname>Yuan</surname> <given-names>J</given-names></name><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Desrichard</surname> <given-names>A</given-names></name><name><surname>Walsh</surname> <given-names>LA</given-names></name><name><surname>Postow</surname> <given-names>MA</given-names></name><name><surname>Wong</surname> <given-names>P</given-names></name><name><surname>Ho</surname> <given-names>TS</given-names></name><name><surname>Hollmann</surname> <given-names>TJ</given-names></name><name><surname>Bruggeman</surname> <given-names>C</given-names></name><name><surname>Kannan</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Elipenahli</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Harbison</surname> <given-names>CT</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Wolchok</surname> <given-names>JD</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title><source>New England Journal of Medicine</source><volume>371</volume><fpage>2189</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmid">25409260</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Nathanson</surname> <given-names>T</given-names></name><name><surname>Funt</surname> <given-names>SA</given-names></name><name><surname>Ahuja</surname> <given-names>A</given-names></name><name><surname>Buros Novik</surname> <given-names>J</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Chang</surname> <given-names>E</given-names></name><name><surname>Aksoy</surname> <given-names>BA</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Yusko</surname> <given-names>E</given-names></name><name><surname>Vignali</surname> <given-names>M</given-names></name><name><surname>Benzeno</surname> <given-names>S</given-names></name><name><surname>Boyd</surname> <given-names>M</given-names></name><name><surname>Moran</surname> <given-names>M</given-names></name><name><surname>Iyer</surname> <given-names>G</given-names></name><name><surname>Robins</surname> <given-names>HS</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Merghoub</surname> <given-names>T</given-names></name><name><surname>Hammerbacher</surname> <given-names>J</given-names></name><name><surname>Rosenberg</surname> <given-names>JE</given-names></name><name><surname>Bajorin</surname> <given-names>DF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in Urothelial Cancer: an exploratory multi-omic analysis</article-title><source>PLOS Medicine</source><volume>14</volume><elocation-id>e1002309</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1002309</pub-id><pub-id pub-id-type="pmid">28552987</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Chlewicki</surname> <given-names>LK</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Liang</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Fu</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade</article-title><source>Cancer Cell</source><volume>29</volume><fpage>285</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.02.004</pub-id><pub-id pub-id-type="pmid">26977880</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Schilling</surname> <given-names>B</given-names></name><name><surname>Shukla</surname> <given-names>SA</given-names></name><name><surname>Blank</surname> <given-names>C</given-names></name><name><surname>Zimmer</surname> <given-names>L</given-names></name><name><surname>Sucker</surname> <given-names>A</given-names></name><name><surname>Hillen</surname> <given-names>U</given-names></name><name><surname>Foppen</surname> <given-names>MHG</given-names></name><name><surname>Goldinger</surname> <given-names>SM</given-names></name><name><surname>Utikal</surname> <given-names>J</given-names></name><name><surname>Hassel</surname> <given-names>JC</given-names></name><name><surname>Weide</surname> <given-names>B</given-names></name><name><surname>Kaehler</surname> <given-names>KC</given-names></name><name><surname>Loquai</surname> <given-names>C</given-names></name><name><surname>Mohr</surname> <given-names>P</given-names></name><name><surname>Gutzmer</surname> <given-names>R</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title><source>Science</source><volume>350</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1126/science.aad0095</pub-id><pub-id pub-id-type="pmid">26359337</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viechtbauer</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Conducting Meta-Analyses in <italic>R</italic> with the metafo<italic>r</italic> package</article-title><source>Journal of Statistical Software</source><volume>36</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.18637/jss.v036.i03</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Jia</surname> <given-names>M</given-names></name><name><surname>He</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>X-S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung Cancer</article-title><source>Oncogene</source><volume>37</volume><fpage>3924</fpage><lpage>3936</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0245-9</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>TIGS (Tumor Immunogenicity Score) project</data-title><version designator="cf1cdcf">cf1cdcf</version><publisher-name>Github</publisher-name><ext-link ext-link-type="uri" xlink:href="https://github.com/XSLiuLab/tumor-immunogenicity-score">https://github.com/XSLiuLab/tumor-immunogenicity-score</ext-link></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>He</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>Xue‐Song</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>The predictive power of tumor mutational burden in lung Cancer immunotherapy response is influenced by patients’ sex</article-title><source>International Journal of Cancer</source><volume>145</volume><fpage>2840</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1002/ijc.32327</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Cowley</surname> <given-names>LA</given-names></name><name><surname>Liu</surname> <given-names>X-S</given-names></name></person-group><year iso-8601-date="2019">2019c</year><article-title>Sex differences in Cancer immunotherapy efficacy, biomarkers, and therapeutic strategy</article-title><source>Molecules</source><volume>24</volume><elocation-id>3214</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24183214</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>The UCSCXenaTools R package: a toolkit for accessing genomics data from UCSC xena platform, from Cancer multi-omics to single-cell RNA-seq</article-title><source>Journal of Open Source Software</source><volume>4</volume><elocation-id>1627</elocation-id><pub-id pub-id-type="doi">10.21105/joss.01627</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarchoan</surname> <given-names>M</given-names></name><name><surname>Hopkins</surname> <given-names>A</given-names></name><name><surname>Jaffee</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor mutational burden and response rate to PD-1 inhibition</article-title><source>New England Journal of Medicine</source><volume>377</volume><fpage>2500</fpage><lpage>2501</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1713444</pub-id><pub-id pub-id-type="pmid">29262275</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>L-G</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>Q-Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Garcia-Diaz</surname> <given-names>A</given-names></name><name><surname>Shin</surname> <given-names>DS</given-names></name><name><surname>Escuin-Ordinas</surname> <given-names>H</given-names></name><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Hu-Lieskovan</surname> <given-names>S</given-names></name><name><surname>Torrejon</surname> <given-names>DY</given-names></name><name><surname>Abril-Rodriguez</surname> <given-names>G</given-names></name><name><surname>Sandoval</surname> <given-names>S</given-names></name><name><surname>Barthly</surname> <given-names>L</given-names></name><name><surname>Saco</surname> <given-names>J</given-names></name><name><surname>Homet Moreno</surname> <given-names>B</given-names></name><name><surname>Mezzadra</surname> <given-names>R</given-names></name><name><surname>Chmielowski</surname> <given-names>B</given-names></name><name><surname>Ruchalski</surname> <given-names>K</given-names></name><name><surname>Shintaku</surname> <given-names>IP</given-names></name><name><surname>Sanchez</surname> <given-names>PJ</given-names></name><name><surname>Puig-Saus</surname> <given-names>C</given-names></name><name><surname>Cherry</surname> <given-names>G</given-names></name><name><surname>Seja</surname> <given-names>E</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Pang</surname> <given-names>J</given-names></name><name><surname>Berent-Maoz</surname> <given-names>B</given-names></name><name><surname>Comin-Anduix</surname> <given-names>B</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Tumeh</surname> <given-names>PC</given-names></name><name><surname>Schumacher</surname> <given-names>TNM</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mutations associated with acquired resistance to PD-1 blockade in melanoma</article-title><source>New England Journal of Medicine</source><volume>375</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1604958</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.49020.035</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Freeman</surname><given-names>Gordon</given-names></name><role>Reviewing Editor</role><aff><institution>Dana-Farber Cancer Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Ji</surname><given-names>Hongbin</given-names> </name><role>Reviewer</role><aff><institution>Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</institution><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Identification of biomarkers that can predict which patients will benefit from immune checkpoint inhibition therapy is clinically important. Wang et al., describe a new computational method to identify responders to immune checkpoint inhibitors by calculating a tumor immunogenicity score (TIGS). TIGS combines tumor mutational burden (TMB) with a gene set score of 18 genes associated with MHC class I Antigen Presentation Machinery (APM) score. They describe the APM score across cancer types in TCGA and correlate APM with other gene expression pathways and immune cell infiltration across cancers. In both a pan-cancer analysis of ICI objective response rates and an ICI clinical response prediction for individual patients, they show that TIGS predicts response to ICI better than TMB alone, PD-L1, immune infiltrate, or Interferon-gene signatures, and somewhat better than the TIDE method based on T cell dysfunction and exclusion gene expression signature. TIGS is a tumor inherent biomarker and may be valuable in predicting response to immunotherapy as well as guiding ways to enhance the immunogenicity of tumors.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Hongbin Ji (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Wang et al. have developed a method named tumor immunogenicity score (TIGS) that combines tumor mutational burden (TMB) and antigen processing and presenting machinery gene expression signature to measure tumor immunogenicity. They found that TIGS could outperform TMB and other known ICI response prediction biomarkers in both pan-cancer ICI objective response rates correlation and ICI clinical response prediction.</p><p>Essential revisions:</p><p>1) The results of Şenbabaoğlu should be cited more fully and their 18 gene APS compared to the 7 gene Şenbabaoğlu APM geneset. The antigen presenting set is all MHC class I. What is the reasoning behind not including MHC class II genes like DRB1, DRB2, CIITA?</p><p>2) TIGS should be compared to TIDE + TMB. Inflamed gene expression signatures have not been shown to be a highly predictive biomarker so I think that comparisons to interferon signatures will show superiority but not guide any advance in our thinking.</p><p>3) Multiple reviewers were perplexed by why high TIGs is associated with good outcome in some tumor types but poorer outcomes in other tumor types (Figure 3B). Expand the discussion here.</p><p>4) Improve the Cox regression analysis as suggested and make the definition of high or low marker expression consistent throughout.</p><p>5) The suggestion to apply the new analyses to many cancer types for ICI response prediction is limited by the available datasets that have all of the required information. The 3 datasets analyzed are what is available and these have been done.</p><p>6) Indicate the source or reference for their linear correlation formula – &quot;objective response rate = 21.4 ×TIGS – 2.7, &quot;.</p><p>7) If a patient has a beta2m mutation, is this captured by the APM signature and TIGS method?</p><p><italic>Reviewer #1:</italic></p><p>Identification of the biomarkers that predict which patients may benefit from immune checkpoint inhibition therapy is clinically important. In this study, Wang et al. developed a method named tumor immunogenicity score (TIGS) that combined tumor mutational burden (TMB) and antigen processing and presenting machinery gene expression signature to measure tumor immunogenicity. They found that TIGS could outperform TMB and other known ICI response prediction biomarkers in both pan-cancer ICI objective response rates correlation and ICI clinical response prediction. Thus, they proposed that TIGS is a potential tumor inherent biomarker for ICI response prediction. Overall, the study is novel and interesting. I list some of my concerns below.</p><p>1) The definition of high or low marker expression should be consistent throughout. For example, the authors defined patients with APS of first quartile as &quot;APS-High&quot;, and those at the fourth quartile as &quot;APS-Low&quot;. In contrast, they defined patients with TIGS above the median as &quot;TIGS-high&quot;, and the remaining as &quot;TIGS-low&quot;. Similar issues exist for the definition of TMB. Please make the correction and explain the rationale behind.</p><p>2) In Figure 3B, Cox regression analysis show that high TIGS is significantly associated with poor survival of patients in several types of malignancies such as adrenocortical carcinoma (HR=5.23, p=0.00105), Kidney Chromophobe (HR=89.9, p=0.01408), Thymoma (HR=8.22, p=0.00198)…etc. How to explain this phenomena given that TIGS reflects tumor immunogenicity and high TIGS predicts favorable prognosis in patients following immunotherapy.</p><p>3) In this study, the authors demonstrate an improved predictive power of TIGS in ICI clinical response when compared to TMB and other gene expression profiling based biomarkers, such as TIDE, IIS, IFNΓ. The authors should discuss the potential mechanisms underlying the superior performance of TIGS for immunotherapy clinical response prediction. The authors state &quot;Furthermore, our linear correlation formula – objective response rate = 21.4 ×TIGS – 2.7, – can be used to.…&quot;. Please also indicate the source or reference for this formula.</p><p><italic>Reviewer #2:</italic></p><p>This well-written article describes a score, the Tumor Immunogenicity Score (TIGS) which combines tumor mutation burden (TMB) and a gene set score of 18 genes associated with Antigen Presentation Machinery (APM) score (APS). The 18 genes were described by Leone et al., 2013) and are PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, TAP1, TAP2, ERAP1, ERAP2, CANX, CALR, PDIA3, TAPBP, B2M, HLA-A, HLA-B, and HLA-C. The author show that the TIGS (product of the natural log of TMB and the normalized APS) marginally outperforms TMB or APS in A) linear associated with Objective Response Rate (ORR), which is a rank order of tissue response to PD1 and PDL1 therapy and B) prediction of response in 2 tissue (Melanoma, Urothelial) in 3 studies (Van Allen, 2015, Hugo et al., 2016 and Snyder et al., 2017).</p><p>This article represents an extension to Şenbabaoğlu et al., 2016 which showed that a 7-gene APM signature of (HLA-A/B/C, B2M, TAP1, TAP2, and TAPBP), that is contained in the authors 18-gene signature was associated of immune infiltration, TMB, and ORR to immune therapy in kidney. Many of the figures presented by the author duplicate or extend that article.</p><p>Some of the figures of APM and APS are redundant with Şenbabaoğlu et al., and I would suggest that these should be moved to the supplement. Instead could the authors should provide a more in-depth discussion of the TIGS scores, IFN etc. Figure 1 should be moved to the supplement.</p><p>Are the APS results different to the 7-gene signature described by Şenbabaoğlu et al., There should be a comparison of the performance of the 7-gene Şenbabaoğlu and the 18-gene signature here.</p><p>Which cells (CIBERSORT scores) or subsets of the IIS scores are most associated with the APS scores.</p><p>The authors should compare their TIGS/APS to recent scores for immune presentation PHBR scores for MHC I and II (Marty et al., 2017 and 2018). https://www.cell.com/cell/pdf/S0092-8674(18)31109-7.pdf https://www.cell.com/cell/pdf/S0092-8674(17)31144-3.pdf</p><p>Does APS correlate with PHBR I alone or does it capture both PHBR scores for MHC class I and II? Does TIGS outperform a product of PHBR and TMB?</p><p>The authors recently stated that TMB is associated with gender (Wang et al., 2019b). What is the association between TIGS, APS and gender.</p><p>In the Introduction, some of the statements are over-generalized and do not reflect the complexity in defining good predictors of immunotherapy response. Whilst a correlation exists, TMB does not always predict response, neither does TIL. Some cancers (e.g. renal) with high immune infiltrate have poor response. Please edit the Introduction to reduce broad over simplifications or generalizations.</p><p><italic>Reviewer #3:</italic></p><p>Wang et al., describe a new computational method to identify responders for immune checkpoint inhibitors (ICI) using gene expression data from the TCGA database. The authors calculate a tumor immunogenicity score (TIGS) by combining tumor mutational burden (TMB) with antigen processing and presentation machinery (APM) gene signatures. They describe APM signatures across cancer types in TCGA and correlate APM with other gene expression pathways and immune cell infiltration across cancers. They next evaluate the ability of TIGS to predict response to ICI and show improved predictions using this method, compared to TMB alone, the TIDE method by Liu and colleagues, and several biomarkers (PDL1, CD8, etc.). This study is timely given the broad interest in predicting clinical responses to ICI therapy, and the concept of combining antigen presentation gene expression with TMB is also novel and interesting. However, the study is lacking in benchmarking data that support the use of the APM gene signature, and in comprehensive comparisons to prior gene signatures that also synergize with TMB in predicting immune response to ICI. It is also unclear whether the authors have evaluated the performance of prior gene signatures combined with TMB, compared to the TIGS method. Without these comparisons, it is difficult for the reader to truly evaluate the value added by this method, and I suspect will result in lower adoption of the method by the community.</p><p>1) A major premise of using antigen presentation gene scores is the presence of mutations in a subset of these genes in non-responder patients (i.e. Zaretsky et al., 2016). Therefore, the authors should determine whether their APM analysis is able to actually capture these defects in tumor samples. In other words, if a patient has a b2m mutation, is this captured by the APM signature and TIGS method? Are these instances the major driver of the value of APM analysis, or are changes in expression levels (without mutation or LOH) also predictive of response?</p><p>2) The authors have compared the performance of TIGS to several other prediction tools, however this analysis is not fully described, and I have several questions:</p><p>- The comparisons to TIDE are interesting. As I understand it, TIDE only takes into account gene expression, and not TMB. In contrast, TIGS takes into account gene expression (APM) and TMB. The authors should show the data for APM signature alone in several of the figures, for example in Figure 5A-C.</p><p>- The authors should also clarify in the main text whether TIDE incorporates TMB into their calculations, and if not, the authors should compare the performance of TIDE +TMB to TIGS.</p><p>- Similarly, for PDL1, IFNΓ, and CD8 scores, were these also combined with TMB? Or were they used in isolation to predict response (Figure 5)? The question is: what is the real value added – is it the APM score, or combining gene expression with TMB?</p><p>- If TIGS remains a better predictor of response compared to TIDE + TMB, the authors should describe in a main figure the performance comparison in all TCGA cancer types, rather than showing the comparison in 3 (2 that currently perform similarly, and 1 where TIGS outperforms). This information, in a main figure, is critical for the reader to understand the value of this new method across many cancers.</p><p>- Since APM genes are turned on by the IFN pathway (as the authors discuss), I would like to see more comprehensive comparisons to IFN pathway signature predictions, beyond only the 6 IFNΓ gene signature score taken from the Ayers et al. manuscript. In particular, I would like to see comparisons to the ISG.RS and IFNΓ.GS signatures described in Benci et al., 2019.</p><p>3) The authors correlate APM score with immune infiltration (using IIS and TIGER). Given the prior concerns regarding data normalization in the TIGER method (Newman et al., 2017), I would suggest adding an additional comparison using CIBERSORT. The correlation of APM and immune cell infiltration is independently interesting (without the prediction of response rates), and I think it would be useful to dig into this a bit more – i.e. which cell types correlate most with high APM scores?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.49020.036</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The results of Şenbabaoğlu should be cited more fully and their 18 gene APS compared to the 7 gene Şenbabaoğlu APM geneset. The antigen presenting set is all MHC class I. What is the reasoning behind not including MHC class II genes like DRB1, DRB2, CIITA?</p></disp-quote><p>As pointed out by the second reviewer, Şenbabaoğlu et al., 2016 performed antigen presentation gene expression signature analysis, our method for analyzing antigen presentation gene expression signature is similar to Şenbabaoğlu et al., 2016 but with different gene list. And this new information about the citation of Şenbabaoğlu et al., 2016 have been included in the first section of Results in the revised manuscript (subsection “APM score definition and pan-cancer analysis”, last paragraph).</p><p>In addition, as suggested, we compared the performance of 7 genes in Şenbabaoğlu et al., 2016 with our 18 genes, results suggested that these two methods show strong association in TCGA pan-cancer level (new Figure 1—figure supplement 1) and similar performance in ICI response prediction (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.49020.023</object-id><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49020-resp-fig1-v1.tif"/></fig><p>MHC I are found on the cell surface of all nucleated cells, and function in displaying peptide fragments of proteins from within the cell to cytotoxic CD8<sup>+</sup> T cells. MHC II are normally found only on professional antigen-presenting cells such as dendritic cells. The antigens presented by MHC II are derived from extracellular proteins. The anti-cancer immune response against mutated peptides (neoantigen) is primarily attributed to MHC-I-restricted cytotoxic CD8<sup>+</sup> T cell responses. MHC-II-restricted CD4<sup>+</sup> T cells also drive anti-tumor responses, however their contribution to neoantigen presentation is not clear.</p><p>This manuscript primarily focused on the cytosolic or endogenous neoantigen presentation pathway mediated by MHC I, this does not mean that the potential neoantigen presentation by MHC II is not important. We agree with the reviewers that MHC II presentation could also contribute to the immunogenicity of cancer cells. And the related new discussion has also been included in the revised Discussion part (Discussion, fifth paragraph).</p><disp-quote content-type="editor-comment"><p>2) TIGS should be compared to TIDE + TMB. Inflamed gene expression signatures have not been shown to be a highly predictive biomarker so I think that comparisons to interferon signatures will show superiority but not guide any advance in our thinking.</p></disp-quote><p>TIDE reflect gene expression signatures of T cell dysfunction and exclusion, it may do not have a similar rationale to be combined with TMB as APS in this study. As suggested, we now include the combination of TIDE and TMB in ICI clinical response prediction (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>). In the Snyder et al., 2017 dataset, combination of TIDE and TMB still show poor ICI response prediction.</p><disp-quote content-type="editor-comment"><p>3) Multiple reviewers were perplexed by why high TIGs is associated with good outcome in some tumor types but poorer outcomes in other tumor types (Figure 3B). Expand the discussion here.</p></disp-quote><p>Most TCGA cancer patients have not been treated with immunotherapy, and the prognosis of these cancer patients are influenced by many factors. Different cancer types could have different prognosis in regards to high APS, TMB or TIGS.</p><p>Meta-analysis with all TCGA cancer types suggests that APS is not associated with cancer patients’ prognosis (new Figure 1B), patients with high TMB tends to have poor prognosis (new Figure 2—figure supplement 3), and this observation is similar to previous studies (Owada-Ozaki et al. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report. J Thorac Oncol. 2018 Aug;13(8):1217-1221; McNamara et al. Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis. Annals of Oncology 30 (Supplement 5): v25–v54, 2019).</p><p>TMB reflect tumor antigenicity, also predict improved survival after immunotherapy. However in cancer patients not treated with immunotherapy, high TMB tends to be associated with poor prognosis, probably because tumor accumulate mutation during progression due to genome instability, and consequently high TMB is usually associated with late stage of cancer.</p><p>High TIGS also tends to associated with poor prognosis. This new data and discussion have now been included in the revised manuscript (new Figure 3B). The poor prognosis associated with high TIGS in cancer patients not treated with immunotherapy may be due to similar mechanism as high TMB. This new data analysis and discussion have now been included in the revised manuscript (subsection “Tumor immunogenicity score (TIGS) definition and pan-cancer profiling”, last paragraph).</p><disp-quote content-type="editor-comment"><p>4) Improve the Cox regression analysis as suggested and make the definition of high or low marker expression consistent throughout.</p></disp-quote><p>Cox regression analysis has now been improved as suggested (see revised Figure 1B, Figure 2—figure supplement 3 and Figure 3B). The definition of high and low markers have now been consistent, and Figure 2 and Figure 2—figure supplement 1 has been edited based on new definition.</p><disp-quote content-type="editor-comment"><p>5) The suggestion to apply the new analyses to many cancer types for ICI response prediction is limited by the available datasets that have all of the required information. The 3 datasets analyzed are what is available and these have been done.</p></disp-quote><p>Thanks for this point, we replied the third reviewer as suggested.</p><disp-quote content-type="editor-comment"><p>6) Indicate the source or reference for their linear correlation formula – &quot;objective response rate = 21.4 ×TIGS – 2.7,&quot;.</p></disp-quote><p>This is based on the linear regression model of Figure 4, and this information has now been included in the revised manuscript (Discussion, third paragraph).</p><disp-quote content-type="editor-comment"><p>7) If a patient has a beta2m mutation, is this captured by the APM signature and TIGS method?</p></disp-quote><p>Our original method for calculating APM score was based on mRNA expression, it does not directly capture mutation status of APM genes. If a patient has a loss of function beta2m mutation, theoretically, this patient will lose the ability to present antigens through MHC I to immune system, and in the revised APS quantification method, the APS will be reset to zero. Loss of function mutation in beta2m is very rare, and we could not find it in both TCGA and three ICI datasets. Therefore changes in expression level appear to be major driver for APS differences.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] 1) The definition of high or low marker expression should be consistent throughout. For example, the authors defined patients with APS of first quartile as &quot;APS-High&quot;, and those at the fourth quartile as &quot;APS-Low&quot;. In contrast, they defined patients with TIGS above the median as &quot;TIGS-high&quot;, and the remaining as &quot;TIGS-low&quot;. Similar issues exist for the definition of TMB. Please make the correction and explain the rationale behind.</p></disp-quote><p>We thank the reviewer for this point. As suggested, we now use the median value as cutoff throughout this study, patients with APS or TMB or TIGS values above the median value were defined as APS-high or TMB-high or TIGS-high respectively. The Figure 2 and Figure 2—figure supplement 1 have thus been corrected based on this new cutoff. Generally the new data do not show apparent difference compared with original one.</p><disp-quote content-type="editor-comment"><p>2) In Figure 3B, Cox regression analysis show that high TIGS is significantly associated with poor survival of patients in several types of malignancies such as adrenocortical carcinoma (HR=5.23, p=0.00105), Kidney Chromophobe (HR=89.9, p=0.01408), Thymoma (HR=8.22, p=0.00198)…etc. How to explain this phenomena given that TIGS reflects tumor immunogenicity and high TIGS predicts favorable prognosis in patients following immunotherapy.</p></disp-quote><p>We thank the reviewer for this point. Most TCGA cancer patients have not been treated with immunotherapy, and the prognosis of these cancer patients are influenced by many factors. Different cancer types could have different prognosis in regards to high APS, TMB or TIGS.</p><p>Meta-analysis with all TCGA cancer types suggests that APS is not associated with cancer patients’ prognosis (new Figure 1B), patients with high TMB tends to have poor prognosis (new Figure 2—figure supplement 3), and this observation is similar to previous studies (Owada-Ozaki et al. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report. J Thorac Oncol. 2018 Aug;13(8):1217-1221; McNamara et al. Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis. Annals of Oncology 30 (Supplement 5): v25–v54, 2019).</p><p>TMB reflect tumor antigenicity, also predict improved survival after immunotherapy. However in cancer patients not treated with immunotherapy, high TMB tends to be associated with poor prognosis, probably because tumor accumulate mutations during progression due to genome instability, and consequently high TMB is usually associated with late stage of cancer.</p><p>High TIGS also tends to associated with poor prognosis. This new data and discussion have now been included in the revised manuscript (new Figure 4B). The poor prognosis associated with high TIGS in cancer patients not treated with immunotherapy may be due to similar mechanism as high TMB. This new data analysis and discussion have now been included in the revised manuscript (subsection “Tumor immunogenicity score (TIGS) definition and pan-cancer profiling”, last paragraph).</p><disp-quote content-type="editor-comment"><p>3) In this study, the authors demonstrate an improved predictive power of TIGS in ICI clinical response when compared to TMB and other gene expression profiling based biomarkers, such as TIDE, IIS, IFNΓ. The authors should discuss the potential mechanisms underlying the superior performance of TIGS for immunotherapy clinical response prediction. The authors state &quot;Furthermore, our linear correlation formula – objective response rate = 21.4 ×TIGS – 2.7, – can be used to.…&quot;. Please also indicate the source or reference for this formula.</p></disp-quote><p>TIGS captured the two key aspects of tumor immunogenicity, tumor antigenicity and antigen presentation, and theoretically this tumor immunogenicity score should have improved prediction power compared to biomarkers that only reflect tumor antigenicity (such as TMB), or tumor immune environment (such as TIDE IFNΓ). As suggested, this new discussion has now been included (Discussion, first paragraph). In the Results section, we also describe the rationale of TIGS (subsection “Tumor immunogenicity score (TIGS) definition and pan-cancer profiling”). The linear correlation formula was based on data in Figure 4C, and this information has been included in the Discussion part (third paragraph).</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>This well-written article describes a score, the Tumor Immunogenicity Score (TIGS) which combines tumor mutation burden (TMB) and a gene set score of 18 genes associated with Antigen Presentation Machinery (APM) score (APS). The 18 genes were described by Leone et al., 2013) and are PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, TAP1, TAP2, ERAP1, ERAP2, CANX, CALR, PDIA3, TAPBP, B2M, HLA-A, HLA-B, and HLA-C. The author show that the TIGS (product of the natural log of TMB and the normalized APS) marginally outperforms TMB or APS in A) linear associated with Objective Response Rate (ORR), which is a rank order of tissue response to PD1 and PDL1 therapy and B) prediction of response in 2 tissue (Melanoma, Urothelial) in 3 studies (Van Allen, 2015, Hugo et al., 2016 and Snyder et al., 2017).</p><p>This article represents an extension to Şenbabaoğlu et al., 2016 which showed that a 7-gene APM signature of (HLA-A/B/C, B2M, TAP1, TAP2, and TAPBP), that is contained in the authors 18-gene signature was associated of immune infiltration, TMB, and ORR to immune therapy in kidney. Many of the figures presented by the author duplicate or extend that article.</p></disp-quote><p>We agree with the reviewer that Şenbabaoğlu et al., 2016 performed a comprehensive study about cancer immune cell infiltration. Şenbabaoğlu et al., 2016 also reported that elevated 7-APM gene expression signature could predict clinical response to Nivolumab (anti-PD-1) in a ccRCC clinical trial, however, this clinical trial only has 6 patients, and their conclusion need to be validated with more patients. Our study focused the immunogenicity of tumor cells, and propose to combine antigen presentation and tumor mutation burden together in quantifying tumor immunogenicity, and thus the major ideas and conclusions of our study are different from Şenbabaoğlu et al., 2016</p><disp-quote content-type="editor-comment"><p>Some of the figures of APM and APS are redundant with Şenbabaoğlu et al., 2016 and I would suggest that these should be moved to the supplement. Instead could the authors should provide a more in-depth discussion of the TIGS scores, IFN etc. Figure 1 should be moved to the supplement.</p></disp-quote><p>We prefer to keep Figure 1 as main figure, Şenbabaoğlu et al., 2016 did show the comparison of APM between normal vs. cancer in 15 TCGA cancer types in their Supplementary Figure 11. The methods for APM calculation have some similarity, however, the focus and data of our Figure 1 and their Supplementary Figure 11 are different. Their study focused on the comparison of APM between cancer vs. normal, however our study focused on the pan-cancer distribution of APS, and this is critical for further compare the pan-cancer ORR in Figure 4. We include the citation of Şenbabaoğlu et al.’s Supplementary Figure 11 data, which show the comparison of APM between cancer vs. normal, in the Results section (subsection “APM score definition and pan-cancer analysis, last paragraph).</p><disp-quote content-type="editor-comment"><p>Are the APS results different to the 7-gene signature described by Şenbabaoğlu et al., 2016 There should be a comparison of the performance of the 7-gene Şenbabaoğlu and the 18-gene signature here.</p></disp-quote><p>The APS generated with our 18 genes and with 7-gene signature described by Şenbabaoğlu et al., 2016 are highly correlated (Figure 1—figure supplement 1), they also show similar prediction power in immunotherapy response prediction (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><disp-quote content-type="editor-comment"><p>Which cells (CIBERSORT scores) or subsets of the IIS scores are most associated with the APS scores.</p></disp-quote><p>We thank the reviewer for this point. As suggested we now included the correlation analysis between APS and cell type status calculated with both CIBERSORT and IIS (new Figure 2—figure supplement 4).</p><disp-quote content-type="editor-comment"><p>The authors should compare their TIGS/APS to recent scores for immune presentation PHBR scores for MHC I and II (Marty et al., 2017 and 2018). https://www.cell.com/cell/pdf/S0092-8674(18)31109-7.pdf https://www.cell.com/cell/pdf/S0092-8674(17)31144-3.pdf</p><p>Does APS correlate with PHBR I alone or does it capture both PHBR scores for MHC class I and II? Does TIGS outperform a product of PHBR and TMB?</p></disp-quote><p>As suggested, we included the comparison between APS and PHBR in the revised manuscript (new Figure 1—figure supplement 1).</p><p>Our APS captures the expression level information of MHC genes in patient level. Patient Harmonic Best Rank (PHBR) score represents antigen presentation ability for mutations. Both PHBR I and II scores are determined by the MHC genotypes of patients. We obtained patient-by-mutation PHBR-I/II score matrix for TCGA patients from the author of PHBR-I/II paper and summarized the median for each patient, followed by calculation of the correlation between APS and PHBR sores in pan-cancer level. The result shows that APS do not correlate with both PHBR I and PHBR II scores (new Figure 1—figure supplement 1).</p><p>PHBR could not capture the antigen presentation differences that exist in different cancer types, since different cancer types should have exactly the same PHBR status because PHBR are MHC genotypes based, thus PHBR cannot be used to explain the ORR differences in cancer types of different tissue origin. On the contrary, our APS and TIGS are gene expression based, and can be used in ORR prediction in different cancer types (Figure 4).</p><p>For ICI clinical response prediction in individual cancer patients, raw sequencing information is not available, and this is required for both HLA typing and mutation calling, thus we reviewed the supplementary files of three immunotherapy datasets and found that only two of them (Van Allen, 2015 and Snyder, 2017) have both MHC-I and mutation information available. We then calculated the PHBR I score for each residue and summarized the median for each patient. The result score was used to predict the immunotherapy response. The analysis process is recorded in https://github.com/XSLiuLab/pypresent/tree/master/icb_analysis. The result shows that TIGS outperform PHBR I alone or PHBR I combined with TMB in immunotherapy clinical response prediction (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><disp-quote content-type="editor-comment"><p>The authors recently that TMB is associated with gender (Wang et al., 2019b). What is the association between TIGS, APS and gender.</p></disp-quote><p>In our IJC 2019 paper, we did observe a significant gender difference in TMB’s prediction power in lung cancer (349 patient, 171 men 178 women). Due to lack of sufficient number of patients, we could not draw significant gender difference in other cancer types. The three ICI datasets with both genomic DNA mutation and RNA expression data available are melanoma and urothelial cancer. In these datasets, we do not have sufficient number of patients to investigate the gender difference in biomarker’s performance. Related discussion has been included in the revised manuscript (Discussion, fifth paragraph).</p><disp-quote content-type="editor-comment"><p>In the Introduction, some of the statements are over-generalized and do not reflect the complexity in defining good predictors of immunotherapy response. Whilst a correlation exists, TMB does not always predict response, neither does TIL. Some cancers (e.g. renal) with high immune infiltrate have poor response. Please edit the Introduction to reduce broad over simplifications or generalizations.</p></disp-quote><p>We thank the reviewer for this point. We edit the Introduction part as suggested (first paragraph).</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>Wang et al., describe a new computational method to identify responders for immune checkpoint inhibitors (ICI) using gene expression data from the TCGA database. The authors calculate a tumor immunogenicity score (TIGS) by combining tumor mutational burden (TMB) with antigen processing and presentation machinery (APM) gene signatures. They describe APM signatures across cancer types in TCGA and correlate APM with other gene expression pathways and immune cell infiltration across cancers. They next evaluate the ability of TIGS to predict response to ICI and show improved predictions using this method, compared to TMB alone, the TIDE method by Liu and colleagues, and several biomarkers (PDL1, CD8, etc.). This study is timely given the broad interest in predicting clinical responses to ICI therapy, and the concept of combining antigen presentation gene expression with TMB is also novel and interesting. However, the study is lacking in benchmarking data that support the use of the APM gene signature, and in comprehensive comparisons to prior gene signatures that also synergize with TMB in predicting immune response to ICI. It is also unclear whether the authors have evaluated the performance of prior gene signatures combined with TMB, compared to the TIGS method. Without these comparisons, it is difficult for the reader to truly evaluate the value added by this method, and I suspect will result in lower adoption of the method by the community.</p><p>1) A major premise of using antigen presentation gene scores is the presence of mutations in a subset of these genes in non-responder patients (i.e. Zaretsky et al., 2016). Therefore, the authors should determine whether their APM analysis is able to actually capture these defects in tumor samples. In other words, if a patient has a b2m mutation, is this captured by the APM signature and TIGS method? Are these instances the major driver of the value of APM analysis, or are changes in expression levels (without mutation or LOH) also predictive of response?</p></disp-quote><p>We thank the reviewer for this point. Our original method for calculating APM score was based on mRNA expression, it does not directly capture mutation status of APM genes. If a patient has a loss of function b2m mutation, theoretically, this patient will lose the ability to present antigens to immune system, and in the revised APM quantification method, the APS will be reset to zero. Loss of function mutation in b2m is very rare, and we could not find it in both TCGA and three ICI datasets. Therefore changes in expression level appear to be major driver for APM differences.</p><disp-quote content-type="editor-comment"><p>2) The authors have compared the performance of TIGS to several other prediction tools, however this analysis is not fully described, and I have several questions:</p><p>- The comparisons to TIDE are interesting. As I understand it, TIDE only takes into account gene expression, and not TMB. In contrast, TIGS takes into account gene expression (APM) and TMB. The authors should show the data for APM signature alone in several of the figures, for example in Figure 5A-C.</p></disp-quote><p>We actually showed the performance of APS in ICI response prediction in the original Figure 5D/E/F.</p><disp-quote content-type="editor-comment"><p>- The authors should also clarify in the main text whether TIDE incorporates TMB into their calculations, and if not, the authors should compare the performance of TIDE +TMB to TIGS.</p></disp-quote><p>TIDE reflect gene expression signatures of T cell dysfunction and exclusion, it may be do not have a similar rationale to be combined with TMB as APS in this study. As suggested we combined TIDE with TMB, and this combination still shows poor predictive power in Snyder et al., 2017 dataset (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><disp-quote content-type="editor-comment"><p>- Similarly, for PDL1, IFNΓ, and CD8 scores, were these also combined with TMB? Or were they used in isolation to predict response (Figure 5)? The question is: what is the real value added – is it the APM score, or combining gene expression with TMB?</p></disp-quote><p>The combination between APS and TMB has been driven by the rationale that tumor immunogenicity can be divided into two independent steps: neoantigen generation through mutation and antigen presentation through MHC, and this information has been described in the Introduction and Results section. In the original manuscript PDL1, IFNΓ and CD8 score has not been combined with TMB, since we could not find proper rationale for the suggested combination between PDL1, IFNΓ or CD8 with TMB. The key information in Figure 5 is that TIGS measured with combined APS and TMB can outperform known biomarkers in ICI clinical response prediction.</p><disp-quote content-type="editor-comment"><p>- If TIGS remains a better predictor of response compared to TIDE + TMB, the authors should describe in a main figure the performance comparison in all TCGA cancer types, rather than showing the comparison in 3 (2 that currently perform similarly, and 1 where TIGS outperforms). This information, in a main figure, is critical for the reader to understand the value of this new method across many cancers.</p></disp-quote><p>Currently we only have three datasets available for analysis. Since ICI datasets that include patients’ genomic data, gene mRNA expression data and clinical response data are very limited, currently only these three datasets are available.</p><disp-quote content-type="editor-comment"><p>- Since APM genes are turned on by the IFN pathway (as the authors discuss), I would like to see more comprehensive comparisons to IFN pathway signature predictions, beyond only the 6 IFNΓ gene signature score taken from the Ayers et al. manuscript. In particular, I would like to see comparisons to the ISG.RS and IFNΓ.GS signatures described in Benci et al., 2019.</p></disp-quote><p>As suggested, we now included ISG.RS and IFNΓ.GS in ICI clinical response prediction comparison (new Figure 5D/E/F).</p><disp-quote content-type="editor-comment"><p>3) The authors correlate APM score with immune infiltration (using IIS and TIGER). Given the prior concerns regarding data normalization in the TIGER method (Newman et al., 2017), I would suggest adding an additional comparison using CIBERSORT. The correlation of APM and immune cell infiltration is independently interesting (without the prediction of response rates), and I think it would be useful to dig into this a bit more – i.e. which cell types correlate most with high APM scores?</p></disp-quote><p>We thank the reviewer for this point. As suggested, we now include CIBERSORT analysis (new Figure 2—figure supplement 4). The cell types correlated with high APS have now been investigated through both CIBERSORT and IIS analysis (new Figure 2—figure supplement 4).</p></body></sub-article></article>